Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update

– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA

®

(brincidofovir) for the Treatment of Smallpox –

– Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter 2021 –

– Conference Call at 8:30 a.m. ET Today –

DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2021 and provided an operational update.

“We made considerable progress throughout the first half of 2021, highlighted by the acquisition of Oncoceutics, the initiation of the Phase 3 DASH AML trial, and the FDA approval of TEMBEXA as a medical countermeasure for smallpox. This approval is an important milestone as it marks Chimerix’s first FDA approved drug and is the first smallpox antiviral approved for all age groups, including infants, with an available oral solution for patients who have difficulty swallowing,” said Mike Sherman, Chief Executive Officer of Chimerix. “Looking ahead to the balance of the year, we expect to report the efficacy analysis by BICR for ONC201 and complete TEMBEXA manufacturing to support U.S. national preparedness.”


Recent Highlights

TEMBEXA for Smallpox

In June, the FDA granted TEMBEXA tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients and is the first and only smallpox therapy approved for neonates. The oral suspension formulation is particularly important for patients who have difficulty swallowing due to age or medical status.

TEMBEXA potentially fills an important role as a treatment countermeasure to smallpox; it has a differentiated mechanism of action, a relatively high barrier to resistance and available evidence suggests it can be used in patients who have received the other approved smallpox antiviral treatment.   By year-end, Chimerix expects to complete initial TEMBEXA drug product manufacturing in order to satisfy a potential procurement contract to support national preparedness in the United States.

Imipridones and ONC201

Chimerix’s acquisition of Oncoceutics, Inc., expands the Company’s oncology franchise with a late-stage, novel class of small molecule anti-cancer compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce tumor cell death in multiple cancer types.

The BICR of radiographic imaging will enable clinical efficacy analyses of the first 50 patients with recurrent H3-K27M-mutant diffuse midline glioma who received single agent ONC201. These analyses will include overall response rate and key supportive endpoints, such as durability of response and other measures of clinical benefit. If favorable, these data may form the basis for an NDA submission seeking accelerated approval of ONC201 in the United States.

In addition, a Phase 1 clinical trial for ONC206, our second imipridone product candidate, and IND-enabling work for our third imipridone candidate, ONC212, remain ongoing.

DSTAT for AML

Chimerix continues enrollment in the Phase 3 Dociparstat in AML with Standard Chemotherapy (DASH AML) study of DSTAT for the treatment of AML. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of DSTAT in combination with standard intensive induction and consolidation chemotherapy for the treatment of newly-diagnosed AML patients. Chimerix expects to unblind data following enrollment of the first 80 evaluable patients in this study to assess complete response rates and minimal residual disease rates between the study arm and the control arm. This analysis is expected to take place in the second half of 2022.


Expected 2021 Milestones

  • Negotiation of a smallpox procurement agreement for TEMBEXA
  • Completion of TEMBEXA drug product manufacturing to support potential shipments up to $100 million for U.S. national preparedness
  • Efficacy analysis by blinded independent central review of 50-subject registration cohort of ONC201 in recurrent H3 K27M-mutant glioma

Second Quarter 2021 Financial Results

Chimerix reported a net loss of $17.8 million, or $0.21 per basic and diluted share, for the second quarter of 2021. During the same period in 2020, Chimerix recorded a net loss of $10.0 million, or $0.16 per basic and diluted share.

Revenues for the second quarter of 2021 decreased to $0.4 million, compared to $1.4 million for the same period in 2020.

Research and development expenses increased to $13.8 million for the second quarter of 2021, compared to $8.6 million for the same period in 2020.

General and administrative expenses increased to $4.4 million for the second quarter of 2021, compared to $3.1 million for the same period in 2020.
Chimerix’s balance sheet at June 30, 2021, included approximately $140 million of capital available to fund operations, $14.0 million in a note payable related to the Oncoceutics transaction and approximately 86.2 million outstanding shares of common stock.

Conference Call and Webcast

Chimerix will host a conference call and live audio webcast to discuss second quarter 2021 financial results and provide a business update today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 6658827.

A live audio webcast of the call will also be available on the Investors section of Chimerix’s website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and an efficacy analysis by blinded independent central review is expected later in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

About TEMBEXA

TEMBEXA is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates. TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease. The effectiveness of TEMBEXA for the treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. TEMBEXA efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals.

TEMBEXA (brincidofovir) is a nucleotide analog lipid-conjugate designed to mimic a natural monoacyl phospholipid to achieve effective intracellular concentrations of the active antiviral metabolite, cidofovir diphosphate. Cidofovir diphosphate exerts its orthopoxvirus antiviral effects by acting as an alternate substrate inhibitor for viral DNA synthesis mediated by viral DNA polymerase.

IMPORTANT SAFETY INFORMATION Including BOXED WARNING

WARNING: INCREASED RISK FOR MORTALITY WHEN USED FOR LONGER DURATION

An increased incidence of mortality was seen in TEMBEXA-treated subjects compared to placebo-treated subjects in a 24-week clinical trial when TEMBEXA was evaluated in another disease

.

WARNINGS AND PRECAUTIONS

Elevations in Hepatic Transaminases and Bilirubin: May cause increases in serum transaminases (ALT or AST) and serum bilirubin. Monitor liver laboratory parameters before and during treatment.

Diarrhea and Other Gastrointestinal Adverse Events: Diarrhea and additional gastrointestinal adverse events including nausea, vomiting, and abdominal pain may occur. Monitor patients, provide supportive care, and if necessary, do not give the second and final dose of TEMBEXA.

Coadministration with Related Products: TEMBEXA should not be co-administered with intravenous cidofovir.

Carcinogenicity: TEMBEXA is considered a potential human carcinogen. Do not crush or divide TEMBEXA tablets and avoid direct contact with broken or crushed tablets or oral suspension.

Male Infertility: Based on testicular toxicity in animal studies, TEMBEXA may irreversibly impair fertility in individuals of reproductive potential.

ADVERSE REACTIONS

Common adverse reactions (adverse events assessed as causally related by the investigator in ≥ 2% of subjects) experienced in the first 2 weeks of dosing with TEMBEXA were diarrhea, nausea, vomiting and abdominal pain.

USE IN SPECIFIC POPULATIONS

Pregnancy

Based on findings from animal reproduction studies, TEMBEXA may cause fetal harm when administered to pregnant individuals. Pregnancy testing should be performed before initiation of TEMBEXA in individuals of childbearing potential to inform risk. An alternative therapy should be used to treat smallpox during pregnancy, if feasible.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the status of Chimerix’s oncology programs, and the potential benefits and government procurement of TEMBEXA. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that the current clinical study data for ONC201 will not support accelerated, or any, regulatory approval; the anticipated benefits of the acquisition of Oncoceutics may not be realized; the ability to generate positive results in a Phase 3 study in acute myeloid leukemia and subsequent approval for DSTAT; risks that Chimerix will not obtain a procurement contract for TEMBEXA in smallpox in a timely manner or at all; Chimerix’s reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT:

Investor Relations:        
Michelle LaSpaluto
919 972-7115
[email protected]

Will O’Connor
Stern Investor Relations
212-362-1200
[email protected]

CHIMERIX, INC.  
CONSOLIDATED BALANCE SHEETS  
(in thousands, except share and per share data)  
(unaudited)  
                 
          June 30,   December 31,  
            2021       2020    
ASSETS          
Current assets:          
  Cash and cash equivalents   $ 25,445     $ 46,989    
  Short-term investments, available-for-sale     106,584       31,973    
  Accounts receivable     36       340    
  Prepaid expenses and other current assets     4,185       2,356    
    Total current assets     136,250       81,658    
Long-term investments     7,535          
Property and equipment, net of accumulated depreciation     298       214    
Operating lease right-of-use assets     2,612       2,825    
Other long-term assets     30       26    
      Total assets   $ 146,725     $ 84,723    
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
  Accounts payable   $ 1,457     $ 1,283    
  Accrued liabilities     9,465       7,250    
  Note payable     14,000          
    Total current liabilities     24,922       8,533    
Lease-related obligations     2,654       2,814    
      Total liabilities     27,576       11,347    
                 
Stockholders’ equity:          
  Preferred stock, $0.001 par value, 10,000,000 shares authorized at June 30, 2021 and          
    December 31, 2020; no shares issued and outstanding as of June 30, 2021 and          
    December 31, 2020              
  Common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2021 and          
    December 31, 2020; 86,249,744 and 62,816,039 shares issued and outstanding as of          
    June 30, 2021 and December 31, 2020, respectively     86       63    
  Additional paid-in capital     946,612       785,673    
  Accumulated other comprehensive loss, net     (11 )        
  Accumulated deficit     (827,538 )     (712,360 )  
    Total stockholders’ equity     119,149       73,376    
      Total liabilities and stockholders’ equity   $ 146,725     $ 84,723    
                 
CHIMERIX, INC.  
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS  
(in thousands, except share and per share data)  
(unaudited)  
                           
             Three Months Ended June 30,   Six Months Ended June 30,  
              2021       2020       2021       2020    
Revenues:                  
  Contract revenue   $ 390     $ 1,396     $ 1,823     $ 2,567    
  Licensing revenue     1       6       3       76    
    Total revenues     391       1,402       1,826       2,643    
Operating expenses:                  
  Research and development     13,798       8,578       25,660       17,527    
  General and administrative     4,408       3,110       8,544       6,315    
  Acquired in-process research and dvelopment                 82,890          
    Total operating expenses     18,206       11,688       117,094       23,842    
      Loss from operations     (17,815 )     (10,286 )     (115,268 )     (21,199 )  
Other income:                  
  Interest income and other, net     52       270       90       763    
        Net loss     (17,763 )     (10,016 )     (115,178 )     (20,436 )  
Other comprehensive loss:                  
  Unrealized gain (loss) on debt investments, net     32       141       (11 )     95    
        Comprehensive loss   $ (17,731 )   $ (9,875 )   $ (115,189 )   $ (20,341 )  
Per share information:                  
  Net loss, basic and diluted   $ (0.21 )   $ (0.16 )   $ (1.38 )   $ (0.33 )  
  Weighted-average shares outstanding, basic and diluted   86,255,836       62,042,778       83,231,600       61,892,407    
                           

 

 

 



Penn National Gaming Reports Second Quarter Revenues of $1,545.8 Million, Net Income of $198.7 Million, Adjusted EBITDAR of $586.6 Million, and Adjusted EBITDA of $470.1 Million

Penn National Gaming Reports Second Quarter Revenues of $1,545.8 Million, Net Income of $198.7 Million, Adjusted EBITDAR of $586.6 Million, and Adjusted EBITDA of $470.1 Million

– PENN Generated Second Quarter Net Income Margin of 13% and Second Quarter Adjusted EBITDAR Margin of 38%, Driven by Strong Demand from Core Gaming Business and More Efficient Cost Structure –

– Focus Remains on Sustaining Core Gaming Business Margin Improvement and Driving Profitable Online Gaming Revenue –

– Penn National to Acquire Score Media and Gaming, Creating North America’s Leading Digital Sports Content, Gaming and Technology Company –

WYOMISSING, Pa.–(BUSINESS WIRE)–
Penn National Gaming, Inc. (NASDAQ: PENN) (“Penn National” or the “Company”) today reported financial results for the three and six months ended June 30, 2021.

2021 Second Quarter Financial Highlights:

  • Revenues of $1,545.8 million, an increase of $1,240 million year over year and $223 million versus 2019;
  • Net income of $198.7 million and net income margin of 12.9%, as compared to a net loss of $214.4 million and (70.2)%, respectively, in the prior year and net income of $51.4 million and net margin of 3.9% in 2019;
  • Adjusted EBITDA of $470.1 million, an increase of $549.4 million year over year and $153.6 million versus 2019;
  • Adjusted EBITDAR of $586.6 million, an increase of $562.1 million year over year and $180.1 million versus 2019; and
  • Adjusted EBITDAR margins of 37.9%, up 2,993 basis points year over year and 722 basis points versus 2019.

For further information, we have posted a presentation to our website regarding the second quarter highlights and accomplishments, which can be found here.

Jay Snowden, President and Chief Executive Officer, commented: “Penn National delivered a strong second quarter that exceeded our pre-announced results from June 24, 2021. For the second quarter ended June 30, 2021, Penn National generated revenues of $1.55 billion, at the high end of our pre-announced range of $1.45 billion to $1.56 billion while Adjusted EBITDAR of $586.6 million exceeded the high end of our $540 million to $580 million range. Compared to Q2 2019 pro forma results, revenues increased 13%, Adjusted EBITDAR grew 38% and Adjusted EBITDAR margins increased 694 basis points. The strong results were driven by exceptional performance across our portfolio of core gaming business properties. Contributions from Barstool Sports, the media company, were also positive. Further, we saw strong revenue growth across our Penn Interactive segment, which operated near breakeven for the quarter despite being live in only four states.

“Separately, this morning Penn National announced that we have entered into a definitive agreement to acquire Score Media and Gaming, which is the number one sports app in Canada and the third most popular sports app in North America. When we add theScore’s unique integrated media and betting platform and modern, state-of-the art technology, to the massive audience of Barstool Sports and its wildly popular personalities and content, we’ll be creating North America’s leading digital sports content, gaming and technology company. We anticipate that the acquisition of theScore will provide adjusted EBITDA accretion by Year 2, an incremental $200 million medium term adjusted EBITDA, and $500 million of incremental long term adjusted EBITDA upside.”

More details regarding the transaction may be found in a separate press release issued today. To access the release, please visit here.

Robust Recovery in our Core Gaming Business Continues

Mr. Snowden stated: “Sequentially improved visitation and length of play across all age segments of our player database led to our record results in the second quarter. Spend-per-visit has remained high since reopening last year, and our overall visitation numbers are encouraging as restrictions continue to be lifted. The traditional core gaming customer has reengaged with our properties as vaccines continue to roll out across the country, while the younger demographic’s engagement continued throughout Q2 and into Q3 despite the increased availability of alternative entertainment options. Overall, our unrated play continues to perform well, and we have been pleased with our ability to convert these customers into our mychoice loyalty program. These noteworthy drivers of our revenue growth combined with the changes we have made to our offerings and our expense structure has led to tremendous flow-through and margin improvement. We have seen this strength across all geographic regions, with the South Region leading the way as demonstrated by the segment’s outsized performance in both revenues and EBITDAR.”

Sportsbook Launch Schedule on Track

Mr. Snowden continued, “We are making great strides in the planned rollout of our Barstool Sportsbook. Following our Indiana launch in May, we anticipate more than doubling our footprint by the start of the 2021 NFL season in early September with upcoming launches in Colorado, New Jersey, Tennessee, Virginia, and Arizona. By the end of the year, we plan to be operating in at least 10 states. Additionally, as we gain scale across the country, we will increase our marketing efforts to further widen the funnel into our omnichannel ecosystem while we remain focused on our measured and profit-driven approach. For example, we recently announced an expansion of our NASCAR relationship with a comprehensive sponsorship and marketing partnership with the Phoenix Raceway. Further, we have agreed to act as the official sports betting partner for the upcoming August 29 boxing event between Tyron Woodley and Jake Paul, which will include Barstool Sportsbook branded segments featuring key personalities.

“We anticipate Penn Interactive will generate meaningful EBITDA contributions beginning in 2023, inclusive of significant planned investments in marketing, product and additional state launches. Not only does Barstool Sports’ creative content, exclusive bets, and social media reach provide a competitive advantage for our mobile sportsbook via low-cost customer acquisition, but it also provides us with the brand leverage to drive our omnichannel strategy as the Barstool audience converts to our core gaming businesses.

“With this in mind, we plan to open/rebrand five more Barstool Sports retail sportsbooks by the end of the year. In addition, we are making progress on the build out of stand-alone Barstool-branded sports bars, with the initial locations in Philadelphia and Chicago scheduled to open later this year. We are also continuing to bolster our iCasino offerings, including the addition of more third-party content, the introduction of a Barstool-branded live dealer studio in New Jersey and the launch of our first in-house developed, Barstool-branded online table and slot games by year-end.

Growth on the Horizon

“We launched our cashless, cardless, and contactless (“3Cs”) technology at Hollywood Casino at Penn National Race Course in late June followed by another successful implementation at the Meadows Casino in mid-July. The 3Cs technology will increase safety and provide improved service while delivering additional efficiencies and accountability. This initiative will also bring our property technology in line with other industries which should resonate with our guests of all ages. We will introduce the 3Cs technology across the Penn enterprise over the next 12 to 18 months, pending regulatory approvals.

“We are very excited to open our Hollywood Casino York facility on August 12, which will be our third casino in the Commonwealth of Pennsylvania, pending final regulatory approval. This casino will feature 500 of the most popular slot machines and 24 table games and include a Barstool Sportsbook. The facility will also be the third casino to feature our 3Cs technology. Our second Category 4 Pennsylvania casino project, Hollywood Casino Morgantown, is on track to open before the end of the year.

“We closed the Hollywood Casino Perryville acquisition on July 1, 2021. We are very excited to be operating again in Maryland, which adds a 20th state to our leading nationwide footprint. We expect to add a branded Barstool Sportsbook to the property and introduce our Barstool Sportsbook mobile app to sports bettors across the state, which will continue to expand our omnichannel presence.

“Finally, Barstool Sports, the media company, has continued to show tremendous growth this year both financially and in terms of audience metrics, as it has continued to evolve into a highly diversified media, entertainment and lifestyle brand. Just recently, Barstool was announced as the title sponsor and exclusive broadcast partner for the Barstool Sports Arizona Bowl, a watershed moment for the industry, as Barstool is redefining the way sports programming is produced and delivered in today’s media landscape. The continued growth and diversification of the company’s revenue streams, including advertising, licensing and merchandise, has meaningfully enhanced the value of the media asset, which we believe is still underappreciated and extends well beyond the benefits to our sports betting business.”

Continuing to Care for our People, our Communities and the Planet

Last month, in conjunction with our celebration of Juneteenth, we marked the one-year anniversary of the launch of our Penn Diversity Committee. Comprised of a diverse group of team members at varying levels in our organization from around the country, the goal of our Diversity Committee is to help put our company’s longstanding stance on Diversity, Equity, and Inclusion into action. Earlier this quarter, we awarded the first scholarships from our Penn Diversity Scholarship Program to 58 children of our team members, totaling $1.05 million. More than half of these diverse awardees represent the first generation of their families to pursue higher education, which is significantly above the national average. In addition, we increased our recruitment efforts and support of Historic Black Colleges and Universities, as well as our support for organizations in our communities promoting equality and justice. We also continue to be committed to the growth of minority-owned businesses and are proud to have recently launched the Penn Minority Business Incubator.

Further, in honor of Armed Forces Day, we launched the “myheroes” program on May 15, which provides veterans, active-duty military and first responders access to exclusive discounts and offers at Penn Properties. In less than a month we had more than 25,000 new member sign ups from around the country. On Memorial Day, we announced the Harold Cramer Memorial Scholarship Fund, which will help veterans pursue a law degree at the University of Pennsylvania Law School. And in June, we celebrated Pride Month and shared stories throughout the month with our team members of LGBTQ champions who have helped change our world.

Finally, on the environmental front, we’re proud to have incorporated all the latest energy efficient enhancements into our two new casinos set to open in York and Morgantown, Pennsylvania. In addition, we’re continuing to focus on reducing our energy footprint at our properties, as well as the amount of water and plastics used across our enterprise.

Enviable Balance Sheet and Liquidity Position

Traditional net debt as of June 30, 2021 was $116 million, a decrease of $237 million during the quarter, principally due an increase in operating cash flows and repayments under our senior secured credit facilities. Our lease-adjusted net leverage was 4.0x based on Adjusted EBITDAR through the trailing 12 months ended June 30, 2021. On July 1, 2021, we closed on an eight-year $400 million unsecured notes offering priced at 4.125%. Pro forma for this transaction, cash on the balance sheet stands at $2.7 billion, which combined with our fully undrawn revolver, drives our liquidity to nearly $3.4 billion positioning us well to execute on our long-term growth strategy.

Summary of Second Quarter Results

 

For the three months ended June 30,

(in millions, except per share data, unaudited)

2021

 

2020

 

2019

Revenues

$

1,545.8

 

 

$

305.5

 

 

$

1,323.1

 

Net income (loss)

198.7

 

 

(214.4

)

 

51.4

 

 

 

 

 

 

 

Adjusted EBITDA (1)

$

470.1

 

 

$

(79.3

)

 

$

316.5

 

Rent expense associated with triple net operating leases (2)

116.5

 

 

103.8

 

 

90.0

 

Adjusted EBITDAR (1)

$

586.6

 

 

$

24.5

 

 

$

406.5

 

Payments to our REIT Landlords under Triple Net Leases, inclusive of rent credits utilized (3)

$

229.1

 

 

$

216.6

 

 

$

214.9

 

 

 

 

 

 

 

Diluted earnings (loss) per common share

$

1.17

 

 

$

(1.69

)

 

$

0.44

 

(1)

See the “Non-GAAP Financial Measures” section below for more information as well as the definitions of Adjusted EBITDA and Adjusted EBITDAR. Additionally, see below for reconciliations of these Non-GAAP financial measures to their GAAP equivalent financial measure.

(2)

Consists of the operating lease components contained within our triple net master lease dated November 1, 2013 with Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (“GLPI”) and the triple net master lease assumed in connection with our acquisition of Pinnacle Entertainment, Inc.(individually referred to as the Penn Master Lease and Pinnacle Master Lease, respectively, and are collectively referred to as our “Master Leases”), which is primarily land, our individual triple net leases with GLPI for the real estate assets used in the operation of Tropicana Las Vegas Hotel and Casino, Inc. and Meadows Racetrack and Casino, and our individual triple net leases with VICI Properties Inc. (NYSE: VICI) for the real estate assets used in the operations of Margaritaville Casino Resort and Greektown Casino-Hotel (referred to collectively as our “triple net operating leases”). During the three months ended June 30, 2021, we recorded noncash rent expense associated with the Tropicana Lease of $10.7 million. The finance lease components contained within our Master Leases (primarily buildings) are recorded to interest expense (as opposed to rent expense) in accordance with Accounting Standards Codification Topic 842, “Leases.”

(3)

Consists of payments made to GLPI and VICI Properties Inc. (referred to collectively as our “REIT Landlords”) under the Master Leases, the Meadows Lease, the Margaritaville Lease, the Greektown Lease and the Morgantown Lease. Although we collectively refer to the Master Leases, the Meadows Lease, the Margaritaville Lease, the Greektown Lease, the Morgantown Lease and the Tropicana Lease as our “Triple Net Leases,” the rent under the Tropicana Lease is nominal. During the three and six months ended June 30, 2020, we utilized rent credits totaling $130.8 million to pay rent under the Penn Master Lease, Pinnacle Master Lease and Meadows Lease.

PENN NATIONAL GAMING, INC. AND SUBSIDIARIES

Segment Information

 

The Company aggregates its properties into four reportable segments: Northeast, South, West and Midwest.

 

 

For the three months ended

June 30,

 

For the six months ended

June 30,

(in millions, unaudited)

2021

 

2020

 

2019

 

2021

 

2020

 

2019

Revenues:

 

 

 

 

 

 

 

 

 

 

 

Northeast segment (1)

$

652.5

 

 

$

102.7

 

 

$

599.1

 

 

$

1,223.4

 

 

$

623.4

 

 

$

1,149.7

 

South segment (2)

368.2

 

 

121.5

 

 

282.2

 

 

664.1

 

 

344.8

 

 

574.1

 

West segment (3)

140.4

 

 

17.7

 

 

164.2

 

 

237.0

 

 

144.3

 

 

322.9

 

Midwest segment (4)

294.8

 

 

36.0

 

 

268.2

 

 

529.5

 

 

264.1

 

 

539.5

 

Other (5)

97.7

 

 

27.6

 

 

9.4

 

 

185.6

 

 

47.9

 

 

19.5

 

Intersegment eliminations (6)

(7.8

)

 

 

 

 

 

(18.9

)

 

(2.9

)

 

 

Total revenues

$

1,545.8

 

 

$

305.5

 

 

$

1,323.1

 

 

$

2,820.7

 

 

$

1,421.6

 

 

$

2,605.7

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDAR:

 

 

 

 

 

 

 

 

 

 

 

Northeast segment (1)

$

231.6

 

 

$

(3.6

)

 

$

186.2

 

 

$

424.8

 

 

$

120.9

 

 

$

351.0

 

South segment (2)

177.1

 

 

44.4

 

 

92.8

 

 

311.0

 

 

97.0

 

 

190.6

 

West segment (3)

61.4

 

 

(3.0

)

 

50.5

 

 

96.6

 

 

21.6

 

 

100.4

 

Midwest segment (4)

142.2

 

 

(4.6

)

 

97.8

 

 

248.2

 

 

64.9

 

 

197.0

 

Other (5)

(25.7

)

 

(8.7

)

 

(20.8

)

 

(47.0

)

 

(27.6

)

 

(41.1

)

Total Adjusted EBITDAR (7)

$

586.6

 

 

$

24.5

 

 

$

406.5

 

 

$

1,033.6

 

 

$

276.8

 

 

$

797.9

(1)

The Northeast segment consists of the following properties: Ameristar East Chicago, Greektown Casino-Hotel (acquired May 23, 2019), Hollywood Casino Bangor, Hollywood Casino at Charles Town Races, Hollywood Casino Columbus, Hollywood Casino Lawrenceburg, Hollywood Casino at Penn National Race Course, Hollywood Casino Toledo, Hollywood Gaming at Dayton Raceway, Hollywood Gaming at Mahoning Valley Race Course, Marquee by Penn, Meadows Racetrack and Casino, and Plainridge Park Casino.

(2)

The South segment consists of the following properties: 1st Jackpot Casino, Ameristar Vicksburg, Boomtown Biloxi, Boomtown Bossier City, Boomtown New Orleans, Hollywood Casino Gulf Coast, Hollywood Casino Tunica, L’Auberge Baton Rouge, L’Auberge Lake Charles, and Margaritaville Resort Casino. Prior to its closure on June 30, 2019, Resorts Casino Tunica was also included in the South segment.

(3)

The West segment consists of the following properties: Ameristar Black Hawk, Cactus Petes and Horseshu, M Resort, Tropicana, and Zia Park Casino.

(4)

The Midwest segment consists of the following properties: Ameristar Council Bluffs; Argosy Casino Alton; Argosy Casino Riverside; Hollywood Casino Aurora; Hollywood Casino Joliet; our 50% investment in Kansas Entertainment, which owns Hollywood Casino at Kansas Speedway; Hollywood Casino St. Louis; Prairie State Gaming; and River City Casino.

(5)

The Other category consists of the Company’s stand-alone racing operations, namely Sanford-Orlando Kennel Club and the Company’s joint venture interests in Sam Houston Race Park, Valley Race Park, and Freehold Raceway; our management contract for Retama Park Racetrack and our live and televised poker tournament series that operates under the trade name, Heartland Poker Tour (“HPT”). The Other category also includes Penn Interactive, which operates social gaming, our internally-branded retail sportsbooks, iGaming and our Barstool Sportsbook mobile app. Expenses incurred for corporate and shared services activities that are directly attributable to a property or are otherwise incurred to support a property are allocated to each property. The Other category also includes corporate overhead costs, which consist of certain expenses, such as: payroll, professional fees, travel expenses and other general and administrative expenses that do not directly relate to or have not otherwise been allocated to a property. For the three months ended June 30, 2021, 2020 and 2019 corporate overhead costs were $26.1 million, $16.7 million and $23.6 million, respectively, compared to $50.1 million, $40.9 million, and $46.7 million, respectively, for the six months ended June 30, 2021, 2020 and 2019. In addition, Adjusted EBITDAR of the Other category includes our proportionate share of the net income or loss of Barstool Sports after adding back our share of non-operating items (such as interest expense, net; income taxes; depreciation and amortization; and stock-based compensation expense).

(6)

Primarily represents the elimination of intersegment revenues associated with our internally-branded retail sportsbooks, which are operated by Penn Interactive.

(7)

As noted within the “Non-GAAP Financial Measures” section below, Adjusted EBITDAR is presented on a consolidated basis outside the financial statements solely as a valuation metric or for reconciliation purposes.

PENN NATIONAL GAMING, INC. AND SUBSIDIARIES

Supplemental Information

Given the COVID-19 pandemic and the resulting temporary closure of all of the Company’s gaming and racing properties in first and second quarter in 2020, the Company believes presenting information regarding the Company’s financial results for the three and six months ended June 30, 2019 is useful to investors to evaluate the Company’s performance for the three and six months ended June 30, 2021.

The Company acquired Greektown on May 23, 2019. Although the Company did not own Greektown from January 1, 2019 through May 22, 2019, the Company believes the following supplemental information is useful to investors to assess the value this transaction brings to the Company and its shareholders. Revenues earned by Greektown prior to the acquisition date of May 23, 2019 during the three and six months ended June 30, 2019, were $49.8 million and $133.5 million, respectively. Adjusted EBITDAR earned by Greektown prior to the acquisition date of May 23, 2019 during the three and six months ended June 30, 2019 were $16.3 million and $43.0 million. The operating results of Greektown were derived from historical financial information. Greektown operating results were adjusted to conform to the Company’s methodology of allocating certain corporate expenses to properties. Revenues and Adjusted EBITDAR earned by Greektown do not reflect any cost savings or revenue synergies from potential operating efficiencies or associated costs to achieve such savings or synergies that are expected to result from the transaction.

The Company ceased operations of Resorts Casino Tunica on June 30, 2019. Revenues earned by Resorts Casino Tunica for the three and six months ended June 31, 2019 were $4.0 million and $9.8 million, respectively. Resorts Casino Tunica generated Adjusted EBITDAR losses for the three and six months ended June 30, 2019 of $1.6 million and $1.4 million, respectively.

PENN NATIONAL GAMING, INC. AND SUBSIDIARIES

Reconciliation of Comparable GAAP Financial Measure to Adjusted EBITDA,

Adjusted EBITDAR, and Adjusted EBITDAR Margin

 

 

For the three months ended

June 30,

 

For the six months ended

June 30,

(in millions, unaudited)

2021

 

2020

 

2019

 

2021

 

2020

 

2019

Net income (loss)

$

198.7

 

 

$

(214.4

)

 

$

51.4

 

 

$

289.6

 

 

$

(823.0

)

 

$

92.3

 

Income tax expense (benefit)

53.1

 

 

(58.4

)

 

18.5

 

 

73.7

 

 

(157.9

)

 

33.4

 

Loss (income) from unconsolidated affiliates

(9.1

)

 

1.7

 

 

(6.2

)

 

(18.7

)

 

(2.4

)

 

(11.9

)

Interest expense, net

138.0

 

 

135.0

 

 

134.7

 

 

273.7

 

 

264.8

 

 

267.0

 

Other income

(2.8

)

 

(29.3

)

 

 

 

(23.9

)

 

(7.5

)

 

 

Operating income (loss)

377.9

 

 

(165.4

)

 

198.4

 

 

594.4

 

 

(726.0

)

 

380.8

 

Stock-based compensation

9.2

 

 

2.9

 

 

3.3

 

 

13.4

 

 

8.9

 

 

6.7

 

Cash-settled stock-based awards variance

(12.4

)

 

16.1

 

 

(3.4

)

 

9.1

 

 

7.2

 

 

(3.0

)

Loss (gain) on disposal of assets

(0.1

)

 

(28.5

)

 

0.4

 

 

(0.2

)

 

(27.9

)

 

0.9

 

Contingent purchase price

1.2

 

 

0.8

 

 

1.0

 

 

1.3

 

 

(1.4

)

 

5.8

 

Pre-opening expenses (1)

(0.4

)

 

3.5

 

 

3.7

 

 

1.2

 

 

6.7

 

 

8.1

 

Depreciation and amortization

81.9

 

 

91.9

 

 

106.0

 

 

163.2

 

 

187.6

 

 

210.1

 

Impairment losses

 

 

 

 

 

 

 

 

616.1

 

 

 

Insurance recoveries, net of deductible charges

 

 

 

 

 

 

 

 

(0.1

)

 

 

Income (loss) from unconsolidated affiliates

9.1

 

 

(1.7

)

 

6.2

 

 

18.7

 

 

2.4

 

 

11.9

 

Non-operating items of equity method investments (2)

1.4

 

 

1.1

 

 

0.9

 

 

3.0

 

 

2.0

 

 

1.9

 

Other expenses (1) (3)

2.3

 

 

 

 

 

 

2.6

 

 

 

 

 

Adjusted EBITDA

470.1

 

 

(79.3

)

 

316.5

 

 

806.7

 

 

75.5

 

 

623.2

 

Rent expense associated with triple net operating leases

116.5

 

 

103.8

 

 

90.0

 

 

226.9

 

 

201.3

 

 

174.7

 

Adjusted EBITDAR

$

586.6

 

 

$

24.5

 

 

$

406.5

 

 

$

1,033.6

 

 

$

276.8

 

 

$

797.9

 

Net income (loss) margin

12.9

%

 

(70.2

)%

 

3.9

%

 

10.3

%

 

(57.9

)%

 

3.5

%

Adjusted EBITDAR margin

37.9

%

 

8.0

%

 

30.7

%

 

36.6

%

 

19.5

%

 

30.6

%

(1)

During 2020 and during the first quarter of 2021, acquisition costs were included within pre-opening and acquisition costs. As of and for the quarter ended June 30, 2021, acquisition costs are presented as part of other expenses.

(2)

Consists principally of interest expense, net; income taxes; depreciation and amortization; and stock-based compensation expense associated with Barstool Sports, Inc. and our Kansas Entertainment, LLC joint venture. We record our portion of Barstool Sports, Inc.’s net income or loss, including adjustments to arrive at Adjusted EBITDAR, one quarter in arrears.

(3)

Consists of finance transformation costs associated with the implementation of our new Enterprise Resource Management system, other non-recurring transaction costs, and non-recurring restructuring charges (primarily severance) associated with a company-wide initiative, triggered by the COVID-19 pandemic, designed to (i) improve the operational effectiveness across our property portfolio; (ii) improve the effectiveness and efficiency of our Corporate functional support area.

PENN NATIONAL GAMING, INC. AND SUBSIDIARIES

Consolidated Statements of Operations and Comprehensive Income (Loss)

 

 

For the three months ended

June 30,

 

For the six months ended

June 30,

(in millions, except per share data, unaudited)

2021

 

2020

 

2019

 

2021

 

2020

 

2019

Revenues

 

 

 

 

 

 

 

 

 

 

 

Gaming

$

1,305.5

 

 

$

259.2

 

 

$

1,062.1

 

 

$

2,387.5

 

 

$

1,162.1

 

 

$

2,096.7

 

Food, beverage, hotel and other

240.3

 

 

46.3

 

 

261.0

 

 

433.2

 

 

259.5

 

 

509.0

 

Total revenues

1,545.8

 

 

305.5

 

 

1,323.1

 

 

2,820.7

 

 

1,421.6

 

 

2,605.7

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

Gaming

620.9

 

 

142.0

 

 

564.1

 

 

1,148.7

 

 

642.9

 

 

1,111.6

 

Food, beverage, hotel and other

148.6

 

 

32.9

 

 

167.6

 

 

271.7

 

 

189.9

 

 

329.3

 

General and administrative

316.5

 

 

204.1

 

 

287.0

 

 

642.7

 

 

511.1

 

 

573.9

 

Depreciation and amortization

81.9

 

 

91.9

 

 

106.0

 

 

163.2

 

 

187.6

 

 

210.1

 

Impairment losses

 

 

 

 

 

 

 

 

616.1

 

 

 

Total operating expenses

1,167.9

 

 

470.9

 

 

1,124.7

 

 

2,226.3

 

 

2,147.6

 

 

2,224.9

 

Operating income (loss)

377.9

 

 

(165.4

)

 

198.4

 

 

594.4

 

 

(726.0

)

 

380.8

 

Other income (expenses)

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

(138.0

)

 

(135.0

)

 

(134.7

)

 

(273.7

)

 

(264.8

)

 

(267.0

)

Income (loss) from unconsolidated affiliates

9.1

 

 

(1.7

)

 

6.2

 

 

18.7

 

 

2.4

 

 

11.9

 

Other

2.8

 

 

29.3

 

 

 

 

23.9

 

 

7.5

 

 

 

Total other expenses

(126.1

)

 

(107.4

)

 

(128.5

)

 

(231.1

)

 

(254.9

)

 

(255.1

)

Income (loss) before income taxes

251.8

 

 

(272.8

)

 

69.9

 

 

363.3

 

 

(980.9

)

 

125.7

 

Income tax benefit (expense)

(53.1

)

 

58.4

 

 

(18.5

)

 

(73.7

)

 

157.9

 

 

(33.4

)

Net income (loss)

198.7

 

 

(214.4

)

 

51.4

 

 

289.6

 

 

(823.0

)

 

92.3

 

Less: Net loss attributable to non-controlling interest

 

 

0.5

 

 

0.2

 

 

0.1

 

 

0.5

 

 

0.2

 

Net income (loss) attributable to Penn National

$

198.7

 

 

$

(213.9

)

 

$

51.6

 

 

$

289.7

 

 

$

(822.5

)

 

$

92.5

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

Basic earnings (loss) per share

$

1.27

 

 

$

(1.69

)

 

$

0.44

 

 

$

1.85

 

 

$

(6.78

)

 

$

0.80

 

Diluted earnings (loss) per share

$

1.17

 

 

$

(1.69

)

 

$

0.44

 

 

$

1.72

 

 

$

(6.78

)

 

$

0.78

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding – basic

156.0

 

 

126.8

 

 

116.0

 

 

155.8

 

 

121.3

 

 

116.1

 

Weighted-average common shares outstanding – diluted

172.7

 

 

126.8

 

 

117.7

 

 

172.8

 

 

121.3

 

 

118.2

 

Selected Financial Information

 

Balance Sheet Data

 

(in millions, unaudited)

June 30, 2021

 

December 31, 2020

Cash and cash equivalents

$

2,274.7

 

 

$

1,853.8

 

 

 

 

 

Bank debt

$

1,595.9

 

 

$

1,628.1

 

Notes (1)

730.5

 

 

730.5

 

Other long-term obligations (2)

64.2

 

 

73.0

 

Total traditional debt

2,390.6

 

 

2,431.6

 

Financing obligation (3)

77.7

 

 

 

Less: Debt discounts and debt issuance costs

(108.0

)

 

(119.0

)

 

$

2,360.3

 

 

$

2,312.6

 

 

 

 

 

Traditional net debt (4)

$

115.9

 

 

$

577.8

(1)

Inclusive of our 5.625% Notes due 2027 and our 2.75% Convertible Notes due 2026.

(2)

Other long-term obligations as of June 30, 2021 primarily includes $52.8 million related to relocation fees due for both Hollywood Gaming at Dayton Raceway and Hollywood Gaming at Mahoning Valley Race Course, and $11.4 million related to our repayment obligation on a hotel and event center located near Hollywood Casino Lawrenceburg.

(3)

Represents cash proceeds received on certain claims of which the principal repayment is contingent and classified as a financing obligation under Accounting Standards Codification Topic 470, “Debt.”

(4)

Traditional net debt in the table above is calculated as “Total traditional debt,” which is the principal amount of debt outstanding (excludes the financing obligation associated with cash proceeds received on certain claims of which the principal repayment is contingent) less “Cash and cash equivalents.”

Cash Flow Data

 

The table below summarizes certain cash expenditures incurred by the Company.

 

 

For the three months ended

June 30,

 

For the six months ended

June 30,

(in millions, unaudited)

2021

 

2020

 

2019

 

2021

 

2020

 

2019

Cash payments to our REIT Landlords under Triple Net Leases (1)

$

229.1

 

 

$

85.8

 

 

$

214.9

 

 

$

455.1

 

 

$

309.6

 

 

$

422.8

 

Cash payments (refunds) related to income taxes, net

$

36.5

 

 

$

(0.1

)

 

$

6.2

 

 

$

27.7

 

 

$

(1.2

)

 

$

4.5

 

Cash paid for interest on traditional debt

$

17.5

 

 

$

20.5

 

 

$

24.0

 

 

$

43.3

 

 

$

54.3

 

 

$

62.5

 

Maintenance capital expenditures

$

24.2

 

 

$

14.5

 

 

$

46.8

 

 

$

39.0

 

 

$

44.2

 

 

$

83.0

 

(1)

Consists of payments made under the Master Leases, the Meadows Lease, the Margaritaville Lease, the Greektown Lease, and the Morgantown Leases, in cash. As previously noted, the cash rent under the Tropicana Lease is nominal. During the three and six months ended June 30, 2020, we utilized rent credits totaling $130.8 million to pay rent under the Penn Master Lease, Pinnacle Master Lease and Meadows Lease.

Non-GAAP Financial Measures

The Non-GAAP Financial Measures used in this press release include Adjusted EBITDA, Adjusted EBITDAR, and Adjusted EBITDAR margin. These non-GAAP financial measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP.

We define Adjusted EBITDA as earnings before interest expense, net; income taxes; depreciation and amortization; stock-based compensation; debt extinguishment and financing charges; impairment losses; insurance recoveries, net of deductible charges; changes in the estimated fair value of our contingent purchase price obligations; gain or loss on disposal of assets; the difference between budget and actual expense for cash-settled stock-based awards; pre-opening expenses; and other. Adjusted EBITDA is inclusive of income or loss from unconsolidated affiliates, with our share of non-operating items (such as interest expense, net; income taxes; depreciation and amortization; and stock-based compensation expense) added back for Barstool Sports, Inc. (“Barstool Sports”) and our Kansas Entertainment, LLC joint venture. Adjusted EBITDA is inclusive of rent expense associated with our triple net operating leases (the operating lease components contained within our triple net master lease dated November 1, 2013 with Gaming and Leisure Properties, Inc. (“GLPI”) and the triple net master lease assumed in connection with our acquisition of Pinnacle Entertainment, Inc. (primarily land), our individual triple net leases with GLPI for the real estate assets used in the operation of Tropicana Las Vegas Hotel and Casino, Inc. and Meadows Racetrack and Casino, and our individual triple net leases with VICI Properties Inc. for the real estate assets used in the operations of Margaritaville Casino Resort and Greektown Casino-Hotel). Although Adjusted EBITDA includes rent expense associated with our triple net operating leases, we believe Adjusted EBITDA is useful as a supplemental measure in evaluating the performance of our consolidated results of operations.

Adjusted EBITDA has economic substance because it is used by management as a performance measure to analyze the performance of our business, and is especially relevant in evaluating large, long-lived casino-hotel projects because it provides a perspective on the current effects of operating decisions separated from the substantial non-operational depreciation charges and financing costs of such projects. We present Adjusted EBITDA because it is used by some investors and creditors as an indicator of the strength and performance of ongoing business operations, including our ability to service debt, and to fund capital expenditures, acquisitions and operations. These calculations are commonly used as a basis for investors, analysts and credit rating agencies to evaluate and compare operating performance and value companies within our industry. In order to view the operations of their casinos on a more stand-alone basis, gaming companies, including us, have historically excluded from their Adjusted EBITDA calculations of certain corporate expenses that do not relate to the management of specific casino properties. However, Adjusted EBITDA is not a measure of performance or liquidity calculated in accordance with GAAP. Adjusted EBITDA information is presented as a supplemental disclosure, as management believes that it is a commonly used measure of performance in the gaming industry and that it is considered by many to be a key indicator of the Company’s operating results.

We define Adjusted EBITDAR as Adjusted EBITDA (as defined above) plus rent expense associated with triple net operating leases (which is a normal, recurring cash operating expense necessary to operate our business). Adjusted EBITDAR is presented on a consolidated basis outside the financial statements solely as a valuation metric. Management believes that Adjusted EBITDAR is an additional metric traditionally used by analysts in valuing gaming companies subject to triple net leases since it eliminates the effects of variability in leasing methods and capital structures. This metric is included as supplemental disclosure because (i) we believe Adjusted EBITDAR is traditionally used by gaming operator analysts and investors to determine the equity value of gaming operators and (ii) Adjusted EBITDAR is one of the metrics used by other financial analysts in valuing our business. We believe Adjusted EBITDAR is useful for equity valuation purposes because (i) its calculation isolates the effects of financing real estate; and (ii) using a multiple of Adjusted EBITDAR to calculate enterprise value allows for an adjustment to the balance sheet to recognize estimated liabilities arising from operating leases related to real estate. However, Adjusted EBITDAR when presented on a consolidated basis is not a financial measure in accordance with GAAP, and should not be viewed as a measure of overall operating performance or considered in isolation or as an alternative to net income because it excludes the rent expense associated with our triple net operating leases and is provided for the limited purposes referenced herein. Adjusted EBITDAR margin is defined as Adjusted EBITDAR on a consolidated basis (as defined above) divided by revenues on a consolidated basis. Adjusted EBITDAR margin is presented on a consolidated basis outside the financial statements solely as a valuation metric.

Each of these non-GAAP financial measures is not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure of comparing performance among different companies. See the table above, which presents reconciliations of these measures to the GAAP equivalent financial measures.

Management Presentation, Conference Call, Webcast and Replay Details

Penn National is hosting a conference call and simultaneous webcast at 9:00 am ET today, both of which are open to the general public. During the call, management will review an earnings presentation that can be accessed here.

The conference call number is 212-231-2907. Please call five minutes in advance to ensure that you are connected prior to the presentation. Questions will be reserved for call-in analysts and investors. Interested parties may also access the live call at www.pngaming.com. Please allow 15 minutes to register and download and install any necessary software. A replay of the call can be accessed for thirty days on the Internet at www.pngaming.com.

This press release, which includes financial information to be discussed by management during the conference call and disclosure and reconciliation of non-GAAP financial measures, is available on the Company’s web site, www.pngaming.com, in the “Investors” section (select link for “Press Releases”).

About Penn National Gaming

With the nation’s largest and most diversified regional gaming footprint, including 42 properties across 20 states, Penn National continues to evolve into a highly innovative omni-channel provider of retail and online gaming, live racing and sports betting entertainment. The Company’s properties feature approximately 50,000 gaming machines, 1,300 table games and 8,800 hotel rooms, and operate under various well-known brands, including Hollywood, Ameristar, and L’Auberge. Our wholly-owned interactive division, Penn Interactive, operates retail sports betting across the Company’s portfolio, as well online social casino, bingo, and iCasino products. In February 2020, Penn National entered into a strategic partnership with Barstool Sports, whereby Barstool is exclusively promoting the Company’s land-based and online casinos and sports betting products, including the Barstool Sportsbook mobile app, to its national audience. The Company’s omni-channel approach is bolstered by the mychoice loyalty program, which rewards and recognizes its over 20 million members for their loyalty to both retail and online gaming and sports betting products with the most dynamic set of offers, experiences, and service levels in the industry.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “expects,” “believes,” “estimates,” “projects,” “intends,” “plans,” “goal,” “seeks,” “may,” “will,” “should,” or “anticipates” or the negative or other variations of these or similar words, or by discussions of future events, strategies or risks and uncertainties. Specifically, forward-looking statements include, but are not limited to, statements regarding: COVID-19; continued demand for the gaming properties that have reopened and the possibility that the Company’s gaming properties may be required to close again in the future due to COVID-19; the impact of COVID-19 on general economic conditions, capital markets, unemployment, and the Company’s liquidity, operations, supply chain and personnel; the potential benefits of the Perryville transaction with Gaming and Leisure Properties, Inc.; the potential benefits of the Hitpoint transaction; the Company’s estimated cash burn and future liquidity, future revenue and Adjusted EBITDAR, including from the Company’s iGaming business in Pennsylvania and Michigan; the expected benefits and potential challenges of the investment in Barstool Sports; the expected launch of the Barstool-branded mobile sports betting product in future states and its future revenue and profit contributions; the Company’s expectations of future results of operations and financial condition, including margins; the Company’s expectations for its properties and the potential benefits of the cashless, cardless and contactless (“3Cs”) technology; the Company’s development projects or its iGaming initiatives; the timing, cost and expected impact of planned capital expenditures on the Company’s results of operations; the anticipated opening dates of the Company’s retail sportsbooks in future states; the Company’s expectations with regard to acquisitions, potential divestitures and development opportunities, as well as the integration of and synergies related to any companies the Company have acquired or may acquire; the outcome and financial impact of the litigation in which the Company is or will be periodically involved; the actions of regulatory, legislative, executive or judicial decisions at the federal, state or local level with regard to our business and the impact of any such actions; the Company’s ability to maintain regulatory approvals for its existing businesses and to receive regulatory approvals for its new business partners; the Company’s expectations with regard to the impact of competition in online sports betting, iGaming and retail/mobile sportsbooks as well as the potential impact of this business line on the Company’s existing businesses; and the performance of the Company’s partners in online sports betting, iGaming and retail/mobile sportsbooks, including the risks associated with any new business, the actions of regulatory, legislative, executive or judicial decisions with regard to online sports betting, iGaming and retail/mobile sportsbooks and the impact of any such actions. Such statements are all subject to risks, uncertainties and changes in circumstances that could significantly affect the Company’s future financial results and business.

Accordingly, the Company cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements. Such factors include, but are not limited to: (a) the magnitude and duration of the impact of the COVID-19 pandemic on general economic conditions, capital markets, unemployment, consumer spending and the Company’s liquidity, financial condition, supply chain, operations and personnel; (b) industry, market, economic, political, regulatory and health conditions; (c) disruptions in operations from data protection breaches, cyberattacks, extreme weather conditions, medical epidemics or pandemics such as the COVID-19, and other natural or man-made disasters or catastrophic events; (d) the Company’s ability to access additional capital on favorable terms or at all; (e) the Company’s ability to remain in compliance with the financial covenants of its debt obligations; (f) actions to reduce costs and improve efficiencies to mitigate losses as a result of the COVID-19 pandemic that could negatively impact guest loyalty and the Company’s ability to attract and retain employees; (g) the outcome of any legal proceedings that may be instituted against the Company or its directors, officers or employees; (h) the impact of new or changes in current laws, regulations, rules or other industry standards; (i) the ability of the Company’s operating teams to drive revenue and margins; (j) the impact of significant competition from other gaming and entertainment operations; (k) the Company’s ability to obtain timely regulatory approvals required to own, develop and/or operate its properties, or other delays, approvals or impediments to completing its planned acquisitions or projects, construction factors, including delays, and increased costs; (l) the passage of state, federal or local legislation that would expand, restrict, further tax, prevent or negatively impact operations in or adjacent to the jurisdictions in which the Company does or seek to do business; (m) the effects of local and national economic, credit, capital market, housing, and energy conditions on the economy in general and on the gaming and lodging industries in particular; (n) our ability to identify attractive acquisition and development opportunities (especially in new business lines) and to agree to terms with, and maintain good relationships with partners and municipalities for such transactions; (o) the costs and risks involved in the pursuit of such opportunities and our ability to complete the acquisition or development of, and achieve the expected returns from, such opportunities; (p) the risk of failing to maintain the integrity of our information technology infrastructure and safeguard our business, employee and customer data (particularly as our iGaming division grows); (q) with respect to new casinos, risks relating to construction, and its ability to achieve its expected budgets, timelines and investment returns; (r) the Company may not be able to achieve the anticipated financial returns from the acquisition of Score Media & Gaming, Inc. (“theScore”), including due to fees, costs and taxes in connection with the integration of theScore and expansion of its betting and content platform; (s) the closing of the acquisition of theScore may be delayed or may not occur at all, for reasons beyond the Company’s control; (t) the requirement to satisfy the closing conditions in the agreement with theScore, including receipt of regulatory approvals and the approval of shareholders of theScore; (u) there is significant competition in the interactive gaming market; (v) potential adverse reactions or changes to business or regulatory relationships resulting from the announcement or completion of the acquisition of theScore; (w) the ability of the Company or theScore to retain and hire key personnel; (x) the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the Company and theScore to terminate the agreement between the companies; (y) the outcome of any legal proceedings that may be instituted against the Company, theScore or their respective directors, officers or employees; and (z) other factors as discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, each as filed with the U.S. Securities and Exchange Commission. The Company does not intend to update publicly any forward-looking statements except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release may not occur.

Justin Sebastiano

Senior VP, Finance & Treasurer

610-373-2400

Joseph N. Jaffoni, Richard Land

JCIR

212-835-8500 or [email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Casino/Gaming Entertainment Online

MEDIA:

Logo
Logo

LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update

LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update

Second Quarter and First Half 2021 Procedure Volumes Increase 70% and 42% over 2020 Levels

Cash and Cash Equivalents of $34.6 Million reflects Cash Utilization of $1.3 Million in the Second Quarter

ORLANDO, Fla.–(BUSINESS WIRE)–
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2021 and provided an update on key strategic and operational initiatives.

“We have made significant progress across a number of fronts. Our commercial operations have rebounded from the COVID-19 pandemic, and we have returned to growing the business as we did prior to pandemic shutdowns and interruptions in 2020. Specifically, we had procedure volume growth of 70% and an increase in total revenue of 57% in the second quarter, as compared to second quarter 2020, as well as a 42% increase in procedure volume in the first half of 2021 as compared to the first half of 2020,” said Nick Curtis, Chief Executive Officer of LENSAR. “On the development side of the business, we continue to progress toward the submission and launch of ALLY™ in 2022, navigating supply-chain challenges to maintain on our first quarter 2022 510(k) filing timeline. At the recent ASCRS Meeting we hosted more than 100 surgeons for demonstrations of the ALLY Adaptive Cataract Treatment System and received an overwhelmingly positive response. The need for technology like ALLY, a fully integrated femtosecond laser and phacoemulsification system, is evident and we are truly excited to deliver a desired and disruptive technology to cataract and refractive surgeons in the near-future.”

Second Quarter 2021 Financial Results

Total revenue for the quarter ended June 30, 2021 was $7.9 million, an increase of $2.9 million, or 57%, compared to total revenue of $5.0 million for the quarter ended June 30, 2020. The increase was primarily driven by increased procedure volume, and to a lesser extent, lease placements. Procedure volume exceeded pre-COVID levels, particularly in the United States, as the Company returned to its history of growth and market expansion.

For the quarter ended June 30, 2021, approximately 90% of our revenue was attributable to recurring sources compared to 78% for the quarter ended June 30, 2020. In the quarter ended June 30, 2020, recurring revenue was uncharacteristically low as it was significantly impacted by suspensions of non-essential medical services due to COVID-19.

Selling, general and administrative expenses for the quarter ended June 30, 2021 were $5.5 million, an increase of $1.5 million, or 37%, compared to $4.0 million for the quarter ended June 30, 2020. The increase was primarily due to increased personnel expenses, which was largely due to stock-based compensation expense, as well as expenses associated with being a public company and returning to normal operations as pandemic restrictions were eased.

Research and development (“R&D”) expenses were $3.0 million and $1.4 million for the quarters ended June 30, 2021, and 2020, respectively, an increase of $1.6 million or 110%. The increase in R&D expense was primarily due to additional costs for the continued development of ALLY in anticipation of a 510(k) filing with the U.S. Food and Drug Administration in the first quarter of 2022, as well as increased personnel costs.

Net loss for the quarter ended June 30, 2021, was $4.4 million, or ($0.47) per share, compared to net loss of $4.5 million, or ($4.20) per share, for the quarter ended June 30, 2020, reflecting a decrease in both dollars and loss per share for the quarter ended June 30, 2021. Included within operating expenses are stock-based compensation expenses recorded for the quarters ended June 30, 2021 and 2020 of $1.4 million and $41,000, respectively. These costs reflect, and are the result of, the Company’s recapitalization and becoming a standalone public company in the fourth quarter of 2020.

Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) for the quarter ended June 30, 2021 was ($3.7) million, compared with ($3.2) million for the quarter ended June 30, 2020. Adjusted EBITDA, which we calculate by adding back stock-based compensation expense to EBITDA, was ($2.3) million for the quarter ended June 30, 2021 and ($3.2) million for the quarter ended June 30, 2020. EBITDA and Adjusted EBITDA are non-GAAP financial measures, and a reconciliation of these measures to net loss is set forth below in this press release.

As of June 30, 2021, the Company had cash and cash equivalents of $34.6 million as compared to $40.6 million at December 31, 2020. Cash utilized in the quarter ended June 30, 2021 was $1.3 million and $6.0 million for first half of 2021. Based on its cash position and operational forecast, the Company believes it has sufficient cash to fund operations through the filing of its 510(k) application and expected launch of ALLY in 2022.

Conference Call:

LENSAR management will host a conference call and live webcast to discuss the second quarter results and provide a business update today, August 5, 2021 at 8:30 a.m. ET.

To participate by telephone, please dial (833) 312-1363 (Domestic) or (236) 712-2498 (International). The conference ID number is 2436922. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The call and webcast replay will be available until August 19, 2021.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s development and the future market potential of ALLY. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “target,” “mission,” “may,” “will,” “would,” “should,” “could,” “target,” “potential,” “project,” “predict,” “contemplate,” “potential,” or the negative thereof and similar words and expressions.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company’s assets and business include, without limitation, its history of operating losses and ability to generate revenue; its ability to maintain, grow market acceptance of and enhance its LENSAR Laser System; the impact of the COVID-19 pandemic and the Company’s ability to grow revenues; the Company’s ability to obtain the necessary clearances or approvals for ALLY; the willingness of patients to pay the price difference for LENSAR products; its ability to grow a U.S. sales and marketing organization; its ability to meet its future capital needs; the impact of any material disruption to the supply or manufacture of the LENSAR Laser Systems; the ability of the Company to compete against competitors that have longer operating histories and more established products than the Company; the Company’s ability to address numerous international business risks; and the other important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, including, but not limited to, its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 to be filed with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com. All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing LENSAR’s views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

The Company prepares and analyzes operating and financial data and non-GAAP measures to assess the performance of its business, make strategic and offering decisions and build its financial projections. The key non-GAAP measures it uses are EBITDA and Adjusted EBITDA.

EBITDA is defined as net loss before interest expense, interest income, income tax expense, depreciation and amortization expenses. EBITDA is a non-GAAP financial measure. EBITDA is specifically disclosed because the Company believes that EBITDA provides meaningful supplemental information for investors regarding the performance of its business and facilitates a meaningful evaluation of actual results on a comparable basis with historical results. Adjusted EBITDA is also a non-GAAP financial measure. The Company believes Adjusted EBITDA, which excludes stock-based compensation expense, provides meaningful supplemental information for investors when evaluating its results and comparing it to peer companies as stock-based compensation expense is a significant non-cash charge due to the recapitalization of the Company. It uses these non-GAAP financial measures in order to have comparable financial results to analyze changes in its underlying business from quarter to quarter. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance and, therefore, any non-GAAP measures it use may not be directly comparable to similarly titled measures of other companies.

A reconciliation of EBITDA and Adjusted EBITDA to their most comparable GAAP financial measure are set forth below.

 

Three Months Ended

June 30,

Six Months Ended

June 30,

(Dollars in thousands)

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net loss

$

(4,362

)

$

(4,497

)

$

(9,544

)

$

(8,183

)

Add: Interest expense

 

 

 

671

 

 

 

 

1,275

 

Less: Interest income

 

(13

)

 

(17

)

 

(31

)

 

(34

)

Add: Depreciation expense

 

342

 

 

331

 

 

670

 

 

808

 

Add: Amortization expense

 

309

 

 

314

 

 

622

 

 

631

 

EBITDA

 

(3,724

)

 

(3,198

)

 

(8,283

)

 

(5,503

)

Add: Stock-based compensation expense

 

1,430

 

 

41

 

 

3,750

 

 

126

 

Adjusted EBITDA

$

(2,294

)

$

(3,157

)

$

(4,533

)

$

(5,377

)

 

LENSAR, Inc.

STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

 

Three Months Ended

June 30,

Six Months Ended

June 30,

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue

Product

$

6,056

 

$

3,993

 

$

11,214

 

$

8,096

 

Lease

 

1,140

 

 

470

 

 

2,251

 

 

1,446

 

Service

 

726

 

 

584

 

 

1,500

 

 

1,411

 

Total revenue

 

7,922

 

 

5,047

 

 

14,965

 

 

10,953

 

Cost of revenue (exclusive of amortization)

Product

 

2,366

 

 

2,262

 

 

4,456

 

 

3,468

 

Lease

 

268

 

 

280

 

 

519

 

 

696

 

Service

 

830

 

 

559

 

 

1,638

 

 

1,275

 

Total cost of revenue

 

3,464

 

 

3,101

 

 

6,613

 

 

5,439

 

Operating expenses

Selling, general and administrative expenses

 

5,518

 

 

4,041

 

 

11,553

 

 

8,820

 

Research and development expenses

 

3,006

 

 

1,434

 

 

5,752

 

 

3,005

 

Amortization of intangible assets

 

309

 

 

314

 

 

622

 

 

631

 

Operating loss

 

(4,375

)

 

(3,843

)

 

(9,575

)

 

(6,942

)

Other income (expense)

Interest expense

 

 

 

(671

)

 

 

 

(1,275

)

Other income, net

 

13

 

 

17

 

 

31

 

 

34

 

Net loss attributable to common stockholders

$

(4,362

)

$

(4,497

)

$

(9,544

)

$

(8,183

)

Net loss per share attributable to common stockholders

Basic and diluted

$

(0.47

)

$

(4.20

)

$

(1.03

)

$

(7.65

)

Weighted-average number of shares used in calculation of net loss per share:

Basic and diluted

 

9,296

 

 

1,070

 

 

9,242

 

 

1,070

 

 

LENSAR, Inc.

BALANCE SHEETS

(In thousands, except per share amounts)

June 30,

2021

December 31,

2020

Assets

Current assets:

Cash and cash equivalents

$ 34,554

$ 40,599

Accounts receivable, net of allowance of $27 and $19, respectively

2,695

2,012

Notes receivable, net of allowance of $9 and $9, respectively

436

444

Inventories

12,449

13,473

Prepaid and other current assets

1,432

1,857

Total current assets

51,566

58,385

Property and equipment, net

734

832

Equipment under lease, net

4,937

3,583

Notes and other receivables, long-term, net of allowance of $6 and $9, respectively

275

452

Intangible assets, net

11,487

12,110

Other assets

3,485

3,758

Total assets

$ 72,484

 

$ 79,120

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$ 2,858

$ 2,481

Accrued liabilities

3,292

4,570

Deferred revenue

1,071

923

Other current liabilities

502

493

Total current liabilities

7,723

8,467

Long-term operating lease liabilities

3,061

3,314

Other long-term liabilities

72

129

Total liabilities

10,856

11,910

Stockholders’ equity:

Preferred stock, par value $0.01 per share, 10,000 shares authorized at June 30, 2021 and December 31, 2020; no shares issued and outstanding at June 30, 2021 and December 31, 2020

Common stock, par value $0.01 per share, 150,000 shares authorized at June 30, 2021 and December 31, 2020; 10,957 and 10,933 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively

110

109

Additional paid-in capital

129,055

125,094

Accumulated deficit

(67,537)

(57,993)

Total stockholders’ equity

61,628

67,210

Total liabilities and stockholders’ equity

$ 72,484

$ 79,120

 

Thomas R. Staab, II, CFO

[email protected]

Lee Roth / Cameron Radinovic

Burns McClellan for LENSAR

[email protected] / [email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Health FDA Medical Devices Infectious Diseases Other Health General Health Optical

MEDIA:

Logo
Logo

ViacomCBS Partners With Sky to Launch Paramount+ in Europe

ViacomCBS Partners With Sky to Launch Paramount+ in Europe

Transformative Distribution Partnership Accelerates Global Expansion of ViacomCBS’ Premium Streaming Service to the UK, Ireland, Italy, Germany, Switzerland and Austria in 2022

Extended Partnership Another Key Step In Sky Aggregation Strategy, To Bring The Best Apps and Content To Sky Q Platform

New Multi-Year Comprehensive Agreement Also Includes Extended Carriage of ViacomCBS’ Pay TV Channels and the Renewal of its Ad Sales Partnership in Select Markets

NEW YORK & LONDON–(BUSINESS WIRE)–
ViacomCBS Networks International (VCNI), a division of ViacomCBS Inc. (NASDAQ: VIAC, VIACA) and Sky, part of Comcast Corporation (NASDAQ: CMCSA), today announced that Paramount+ will launch on Sky platforms in the UK, Ireland, Italy, Germany, Switzerland and Austria (GSA) in 2022 as part of a new multi-year distribution agreement that also includes the extended carriage of ViacomCBS’ leading portfolio of pay TV channels and the renewal of Sky as an ad sales partner in select markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005410/en/

“We are thrilled to expand our long-standing partnership with Sky to continue delivering ViacomCBS’ leading portfolio of premium entertainment brands to Sky customers and importantly bring Paramount+ to new audiences in all Sky markets, including the UK, Ireland, Italy, and GSA,” said Raffaele Annecchino, President and Chief Executive Officer, ViacomCBS Networks International. “This transformative distribution deal is key to accelerating our global ambitions in streaming while also supporting Sky’s strategic objectives to better serve audiences with greater flexibility in how they consume our content across all platforms.”

Paramount+ is the latest in a series of apps to come to Sky Q adding more than 10,000 hours of content, further enhancing Sky’s aggregation strategy and enabling Sky customers to watch even more of the best content together in one place on the Sky Q platform.

Stephen van Rooyen, Executive VP & Chief Executive, UK & Europe at Sky said: “This is another example of how we are innovating for our customers and further aggregating all the best apps and content together in one place on Sky Q, giving them more great TV to watch than ever before. Paramount+ is an excellent service with a huge range of fantastic films and TV series, and our new, broader agreement with ViacomCBS will benefit both businesses.”

Upon launch, Sky Cinema subscribers will get the bonus of Paramount+ included at no additional cost, providing access to two fantastic services side by side with more than 10,000 hours of extra content for one affordable price. As part of this partnership, Paramount Pictures’ feature films will remain available on Sky Cinema in the UK and will join Sky Cinema in Germany and Italy in 2022. All other Sky customers will be able to subscribe to Paramount+ as an add-on to their account.

Paramount+ features an expansive catalog of original series, hit shows and popular movies across every genre from world-renowned brands and production studios, including SHOWTIME®, BET, CBS, Comedy Central, MTV, Nickelodeon, Paramount Pictures and the Smithsonian Channel, in addition to a robust offering of premier local content. Outside of the United States, the premium streaming service offers nearly 3,000 episodes of kids’ content, 1,000 episodes of reality, more than 500 films, and 2,500 hours of Paramount+ Originals, CBS and SHOWTIME® series, dramas, and sitcoms.

Titles that will become available through 2022 in the UK, Ireland, Italy and GSA include a collection of scripted, exclusive Paramount+ Originals and exciting new takes on iconic franchises, including HALO, The Offer and the new iCarly series. As the international home of SHOWTIME, the service will offer The Man Who Fell to Earth, Ripley, Super Pumped, and American Gigolo, in addition to popular titles from ViacomCBS, such as Kamp Koral: SpongeBob’s Under Years, Star Trek: Prodigy, and MTV Unplugged. The service will also feature a collection of new movie premieres and fan favorites from Paramount Pictures such as films from the Mission Impossible and Transformer franchises.

In addition, ViacomCBS and Sky reached a multi-year extension for carriage of ViacomCBS’ linear channels — including Comedy Central, MTV and Nickelodeon — in the UK, Ireland, Italy and GSA. The channels will be complemented by a strong selection of box sets, giving customers the flexibility to watch the content they love whenever and wherever they want.

ViacomCBS renewed its multi-year agreement with Sky as an ad sales partner for all platforms and channels in the UK and Italy. Sky Media will continue to handle ad sales across the ViacomCBS portfolio of channels, including Channel 5 in the UK, where ViacomCBS and Channel 5 will benefit from Sky Media’s market-leading innovation in addressable advertising.

Other terms of the agreements were not disclosed.

Paramount+ will also be available direct-to-consumer in UK, Ireland, Italy and GSA through the Paramount+ app for iOS and Android and across supported connected TV devices and OTT platforms. Pricing and local content offering will be announced at a later date.

About Paramount+

Paramount+ is a global digital subscription video streaming service from ViacomCBS that features a mountain of premium entertainment for audiences of all ages. Internationally, the streaming service features an expansive library of original series, hit shows and popular movies across every genre from world-renowned brands and production studios, including SHOWTIME, BET, CBS, Comedy Central, MTV, Nickelodeon, Paramount Pictures and the Smithsonian Channel, in addition to a robust offering of premier local content. Launched on March 4, 2021, the service is currently available in the U.S., Canada, Latin America, and the Nordics, with Australia to launch August 11, 2021. By the end of 2021, ViacomCBS will have launched Paramount+ in 25 markets, ramping to 45 markets by the end of 2022.

For more information about Paramount+, please visit www.paramountplus.com and follow @ParamountPlus on social platforms.

About ViacomCBS Networks International (VCNI)

ViacomCBS Networks International (VCNI), a unit of ViacomCBS Inc. (NASDAQ: VIAC), is comprised of many of the world’s most iconic consumer brands. Its portfolio includes Channel 5, Telefe, Network 10, Nickelodeon, MTV, Comedy Central, BET, Paramount Network, as well as streaming services Paramount+ and PlutoTV, and ViacomCBS International Studios, among others. In addition to offering innovative streaming services and digital video products, ViacomCBS Networks International provides powerful capabilities in production, distribution, and advertising solutions for partners on five continents and across more than 180 countries.

VIAC-IR

About Sky

Sky is Europe’s leading media and entertainment company and is part of Comcast Corporation, a global media and technology company. Across six countries, we connect our 23 million customers to the best entertainment, sports, news and arts including our own award-winning original content.

Our technology, including the market leading Sky Q, connects people to everything they love – with entertainment from Sky TV, Netflix, Disney+, Amazon Prime Video and BBC iPlayer, and apps like Spotify, YouTube, BBC Sounds, Highbrow, Peloton, Fiit, and more, in one place, easy. Our streaming service NOW brings viewers all the enjoyment of Sky with the flexibility of a contract-free service. Through our new B2B broadband provider, Sky Connect, we offer superfast broadband with business-grade 4G back-up to small businesses in the UK.

Building on the success of Sky Originals like Chernobyl, Gangs of London and Brassic, we are doubling our investment in original content by 2024 through Sky Studios. Sky News provides impartial and trustworthy journalism for free, Sky Arts is the UK’s only dedicated free-to-air arts channel making the arts accessible for everyone and Sky Sports, our leading sports broadcasting service, brings customers some of the biggest and best global sporting events from the Premier League to Formula 1 and everything in-between.Our new TV and movie studio, Sky Studios Elstree, which will open in 2022, is expected to create over 2,000 new jobs and generate an additional £3 billion of production investment in the UK over the first five years.

We believe that we can be a force for good in the communities in which we operate. We’re committed to being Europe’s first net zero carbon entertainment company by 2030 and we’re proud to be a Principal Partner and Media Partner of COP26. We take pride in our approach to diversity and inclusion: we’ve been recognised by The Times and Stonewall for our commitment to diversity and we’ve set ambitious 2025 targets to continue to increase diversity and representation. We’re also committed to investing £30million across our markets over three years to improve our approach to diversity and inclusion, and to tackle racial injustice.

ViacomCBS Networks International

Kate Laverge

Senior Vice President, Communications

1-347.754.1677

[email protected]

Ashley Priest

Director, Communications

1-646-285-6081

[email protected]

Sky

Andrew Swailes

Group Director of Corporate Communications

+44 7975 688993

[email protected]

Stuart Mawhinney

Head of Corporate Communications

+44 7772 696325

[email protected]

KEYWORDS: Europe United States United Kingdom North America New York

INDUSTRY KEYWORDS: Entertainment Communications TV and Radio Online Mobile Entertainment Public Relations/Investor Relations

MEDIA:

Logo
Logo
Logo
Logo
Logo
Logo

Radius Health, Inc.: Second Quarter and Year-to-Date Results

  • Repositioned the Company to create meaningful P+L operating leverage
  • Dramatic improvement in Adj. EBITDA performance: ($6) million in Q2, 2021 vs. ($29) million in Q2, 2020
  • FY 2021 guidance: reiterate Adj. EBITDA of $10 million while reducing TYMLOS revenue from $250 to $240 million
  • TYMLOS Q2, 2021 net revenue: $52 million, +3% year-over-year
  • TYMLOS new patient growth: Q2, 2021, up 40+% vs. Q2, 2020 and 1H, 2021 up 18% vs. 1H, 2020
  • Successful elacestrant BE study: established bioequivalence between clinical and commercial supply

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the second quarter ended June 30, 2021 and year-to-date. In addition, the Company provided an update on components of the business.

“Over the past 12 months we have focused on repositioning the business in a comprehensive manner,” said Kelly Martin, Radius’ President and CEO. Martin continued, “within this effort three specific goals warrant being highlighted. They are, to become a cash flow positive company, to complete enrollment and execute our three ongoing pivotal trials in a high-quality manner, and opportunistically add assets that have the potential to enhance the Company’s value proposition. While there is still more to do, significant progress on all three of these objectives has been made to date.”

Q2 and YTD FINANCIAL HIGHLIGHTS:

  • Total Net Revenue vs. prior year:
    • $52 million in Q2, 2021 vs. $50 million in Q2, 2020, +3% year-over-year
    • $108 million 1H, 2021 vs. $98 million 1H, 2020, +10% year-over-year
  • TYMLOS Net Revenue:
    • $52 million in Q2, 2021 vs. $50 million in Q2, 2020, +3% year-over-year
    • $97 million 1H, 2021 vs. $98 million 1H, 2020, -1% year-over-year
  • Total Company Adjusted EBITDA:
    • ($6) million in Q2, 2021 vs. ($29) million in Q2, 2020
    • ($11) million 1H, 2021 vs. ($55) million 1H, 2020
  • FY 2021 guidance: reiterate Adj. EBITDA of $10 million; while reducing TYMLOS revenue from $250 to $240 million
  • Liquidity position: $100 million of cash, cash equivalents and marketable securities as of 6/30/2021

ABALOPARATIDE COMMERCIAL UPDATE:

Patient growth continues in both quarter-over-quarter and year-over-year periods. Progress on business and market segment includes:

  • TYMLOS year-over-year new patient growth of 40+% in Q2, 2021 and 18% in 1H, 2021
  • Top 500 prescribers accounted for ~50% of new patients in Q2, 2021 vs. ~32% in Q1, 2021
  • In Q2, 2021, ~50% of our top 125 prescribers were orthopedic or spine-focused practices
  • New patient growth attributable to ortho/spine and bone health prescribers accelerated vs. prior quarter

As a reflection of the timing of new patient adds, we are reducing our FY 2021 TYMLOS net revenue guidance by $10 million. Given new patient growth during Q4, 2020 and 1H, 2021, we anticipate that the net revenue for TYMLOS in 2H, 2021 will be stronger than 1H, 2021.

The Company remains focused on making further progress in the commercial market space by concentrating resources, time, and effort on postmenopausal women with osteoporosis at high risk of fracture, including those with recent fractures.

ELACESTRANT UPDATE:

In partnership with the Menarini Group, progress continues to be made on the elacestrant asset and pivotal trial. The topline readout is still expected to occur in 2H, 2021 as previously communicated.

Importantly, there was a successful outcome in the completion of the bioequivalency study (BE study). This critical path item establishes equivalency between the clinical trial product and commercial product and is an important step forward on the progression of the asset.

Life cycle discussions and planning have been held with Menarini, and will continue to take place, regarding the possible therapeutic applications of elacestrant within the selective estrogen degrader (SERD) space.

RAD011 UPDATE:

As announced in a press release on July 23, Radius plans to initiate a seamless Phase 2/3 pivotal trial for patients with Prader-Willi Syndrome (PWS) in Q4, 2021 or early Q1, 2022. This trial will be global and incorporates feedback from the FDA, the KOL community as well as input from patient advocacy organizations.


Second Quarter 2021 Financial Results

Three Months Ended June 30, 2021

Net Loss

For the three months ended June 30, 2021, Radius reported a net loss of $16.8 million, or $0.35 per share, compared to a net loss of $43.9 million, or $0.95 per share, for the three months ended June 30, 2020.

For the three months ended June 30, 2021, non-GAAP adjusted net loss, was $10.5 million, or $0.22 per share, compared to non-GAAP adjusted net loss of $31.1 million, or $0.67 per share, for the three months ended June 30, 2020.

Revenue

For the three months ended June 30, 2021, TYMLOS net product revenues were $51.8 million compared to $50.1 million for the three months ended June 30, 2020.

Costs and Expenses

For the three months ended June 30, 2021, research and development expense was $27.0 million compared to $44.9 million for the three months ended June 30, 2020, a decrease of $17.9 million, or 40%. This decrease was primarily driven by a decrease of $10.6 million in abaloparatide-TD program cost, a $0.4 million decrease in occupancy and depreciation costs, a $4.6 million decrease in compensation expense, which is comprised of a $1.7 million decrease in compensation expense related to headcount and $2.9 million of billed reimbursable expenses, and a $8.8 million decrease in elacestrant program costs, which is comprised of a $6.6 million increase in gross program expenses offset by $15.4 million of billed reimbursable expenses. These decreases were offset by a $0.8 million increase in abaloparatide-SC program costs, a $3.6 million increase in RAD011 program costs, and a $2.1 million increase in professional fees and other expenses.

For the three months ended June 30, 2021, selling, general and administrative expenses were $32.1 million compared to $38.2 million for the three months ended June 30, 2020, a decrease of $6.1 million, or 16%. This decrease was primarily the result of a $2.6 million decrease in compensation cost, a $3.9 million decrease in professional support costs, and a $0.2 million decrease in occupancy and depreciation costs. These decreases were partially offset by a $0.5 million increase in travel and entertainment costs, and a $0.1 million increase in other operating costs.

Six Months Ended June 30, 2021

Net Loss

For the six months ended June 30, 2021, Radius reported a net loss of $32.6 million, or $0.69 per share, compared to a net loss of $81.5 million, or $1.76 per share, for the six months ended June 30, 2020.

For the six months ended June 30, 2021, non-GAAP adjusted net loss, was $19.0 million, or $0.40 per share, compared to non-GAAP adjusted net loss of $58.6 million, or $1.26 per share, for the six months ended June 30, 2020.

Revenue

For the six months ended June 30, 2021, TYMLOS net product revenues were $97.1 million compared to $98.0 million for the six months ended June 30, 2020.

For the six months ended June 30, 2021, license revenue was $11.0 million. No license revenue was recognized for the six months ended June 30, 2020.

Costs and Expenses

For the six months ended June 30, 2021, research and development expense was $58.4 million compared to $83.9 million for the six months ended June 30, 2020, a decrease of $25.5 million, or 30%. This decrease was primarily driven by a decrease of $14.0 million in abaloparatide-TD program cost, a $0.2 million decrease in RAD140 program costs, a $0.8 million decrease in occupancy and depreciation costs, a $9.3 million decrease in compensation expense, which is comprised of a $2.8 million decrease in compensation expense related to headcount and $6.5 million of billed reimbursable expenses, and a $16.4 million decrease in elacestrant program costs, which is comprised of a $9.6 million increase in gross program expenses offset by $26.0 million of billed reimbursable expenses. These decreases were offset by a $6.1 million increase in abaloparatide-SC program costs, a $3.6 million increase in RAD011 program costs, and a $5.8 million increase in professional fees and other expenses.

For the six months ended June 30, 2021, selling, general and administrative expenses were $66.2 million compared to $74.7 million for the six months ended June 30, 2020, a decrease of $8.4 million, or 11%. This decrease was primarily the result of a $2.0 million decrease in professional support costs, a $6.1 million decrease in compensation cost, and a $0.3 million decrease in other operating costs.

Consolidated Balance Sheets

(Amounts in thousands, except share and per share amounts)

  June 30,     December 31,  
  2021     2020  
               
ASSETS              
Current assets:              
Cash and cash equivalents $ 99,173     $ 91,436  
Restricted cash   567       567  
Marketable securities         23,280  
Accounts receivable, net   23,638       20,310  
Inventory   11,310       9,174  
Prepaid expenses   11,402       13,279  
Other current assets   38,461       22,502  
Total current assets   184,551       180,548  
Property and equipment, net   702       796  
Intangible assets   5,385       5,785  
Right of use assets – operating leases   740       3,933  
Other assets   1,487       520  
Total assets $ 192,865     $ 191,582  
               
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)              
Current liabilities:              
Accounts payable $ 14,562     $ 9,925  
Accrued expenses and other current liabilities   66,085       59,758  
Deferred Revenue         1,000  
Operating lease liability, current   1,121       2,490  
Total current liabilities   81,768       73,173  
               
Convertible notes payable   190,065       213,645  
Term loan   147,848       24,905  
Operating lease liability, long term   261       3,518  
Total liabilities   419,942       315,241  
               
Stockholders’ equity (deficit):              
Common stock, $0.0001 par value; 200,000,000 shares authorized, 47,255,094
shares and 46,779,479 shares issued and outstanding at June 30, 2021 and
December 31, 2020, respectively
  5       5  
Additional paid-in-capital   1,103,282       1,222,137  
Accumulated other comprehensive income (loss)         21  
Accumulated deficit   (1,330,364 )     (1,345,822 )
Total stockholders’ equity (deficit)   (227,077 )     (123,659 )
Total liabilities and stockholders’ equity (deficit) $ 192,865     $ 191,582  

Consolidated Statement of Operations and Comprehensive Loss

(Amounts in thousands, except share and per share amounts)

  Three Months Ended     Six Months Ended  
  June 30,     June 30,  
  2021     2020     2021     2020  
                               
REVENUES:          
Product revenue, net $ 51,797     $ 50,113     $ 97,057     $ 98,037  
License Revenue               11,000        
Total Revenue   51,797       50,113       108,057       98,037  
OPERATING EXPENSES:                              
Cost of sales – product   4,394       4,070       8,319       7,931  
Cost of sales – intangible amortization   200       200       399       399  
Research and development, net of amounts reimbursable
(a)
  26,950       44,881       58,391       83,890  
Selling, general, and administrative   32,143       38,231       66,240       74,664  
Income (Loss) from operations   (11,890 )     (37,269 )     (25,292 )     (68,847 )
OTHER (EXPENSE) INCOME:                              
Other income (expense)   (79 )     (68 )     (80 )     (59 )
Interest expense   (4,847 )     (6,922 )     (9,211 )     (13,678 )
Interest income   6       379       64       1,050  
Gain on extinguishment of debt               1,960        
NET LOSS $ (16,810 )   $ (43,880 )   $ (32,559 )   $ (81,534 )
OTHER COMPREHENSIVE LOSS:                              
Unrealized gain (loss) from available-for-sale debt
securities
        774       (21 )     105  
COMPREHENSIVE LOSS $ (16,810 )   $ (43,106 )   $ (32,580 )   $ (81,429 )
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS
– BASIC AND DILUTED:
$ (16,810 )   $ (43,880 )   $ (32,559 )   $ (81,534 )
LOSS PER SHARE:                              
Basic and diluted $ (0.35 )   $ (0.95 )   $ (0.69 )   $ (1.76 )
WEIGHTED AVERAGE SHARES:                              
Basic and diluted   47,391,530       46,420,046       47,114,947       46,345,585  
                               
                               
(a) Amounts reimbursable for the three and six months ended June 30, 2021 were $18.5 million and
$32.8 million, respectively, and $0 for the three and six months ended June 30, 2020.
                 
                   

Reconciliation of GAAP to Non-GAAP Financial Information

(Unaudited amounts in thousands, except share and per share amounts)

  Three Months Ended     Six Months Ended  
  June 30,     June 30,  
  2021     2020     2021     2020  
                               
Net loss reconciliation:          
GAAP net loss $ (16,810 )   $ (43,880 )   $ (32,559 )   $ (81,534 )
Intangible amortization   200       200       399       399  
Stock-based compensation expense   5,703       7,840       11,113       13,299  
Restructuring charges                      
Depreciation   42       256       94       548  
Non-cash interest   413       4,436       771       8,725  
Gain on extinguishment of debt               (1,960 )      
Debt refinancing charges               3,143        
Non-GAAP net loss $ (10,452 )   $ (31,148 )   $ (18,999 )   $ (58,563 )
                               
Reconciliation of diluted loss per share:                              
GAAP loss per share $ (0.35 )   $ (0.95 )   $ (0.69 )   $ (1.76 )
Intangible amortization   0.01       0.01       0.01       0.01  
Stock-based compensation expense   0.11       0.16       0.23       0.29  
Restructuring charges                      
Depreciation         0.01             0.01  
Non-cash interest   0.01       0.10       0.02       0.19  
Gain on extinguishment of debt               (0.04 )      
Debt refinancing charges               0.07        
Non-GAAP loss per share $ (0.22 )   $ (0.67 )   $ (0.40 )   $ (1.26 )
                               
Reconciliation of shares used in loss per share calculation:                              
GAAP shares used in loss per share   47,391,530       46,420,046       47,114,947       46,345,585  
Non-GAAP dilutive share adjustments                      
Non-GAAP shares used in loss per share   47,391,530       46,420,046       47,114,947       46,345,585  


Webcast and Conference Call

In connection with today’s reporting of Second Quarter 2021 Financial Results, Radius will host a conference call and live audio webcast at 8:30 a.m. ET today, August 5, 2021, to review the commercial, research and development, and financial highlights and provide a Company update.

Conference Call Information:

Date: August 5, 2021
Time: 8:30 a.m. ET
Domestic Dial-In Number: 1 (800) 446-1671
International Dial-In Number: 1 (847) 413-3362
Conference ID: 50202646
Webcast Link:https://edge.media-server.com/mmc/p/3bncvtkf

A live audio webcast of the call can be accessed from the Investors section of the Company’s website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company’s website.

A replay of the conference call will be available on August 5 at 11:30 a.m. ET and the audio webcast of the call will be archived on the Company’s website for ninety days. To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 3659752. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Company’s website.

Use of Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States (GAAP), we use the following non-GAAP financial measures in this press release: non-GAAP adjusted net loss and non-GAAP net loss per share. These non-GAAP financial measures exclude certain amounts or expenses from the corresponding financial measures determined in accordance with GAAP. Management believes this non-GAAP information is useful for investors, taken in conjunction with Radius’ GAAP financial statements, because it provides greater transparency and period-over-period comparability with respect to Radius’ operating performance and can enhance investors’ ability to identify operating trends in our business. Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Radius’ operating results as reported under GAAP, not in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between these non-GAAP financial measures and the most comparable GAAP financial measures for the three months ended June 30, 2021 and 2020 are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements.

About Radius

Radius is a commercial biopharmaceutical company committed to serving patients with unmet medical needs in endocrinology and other therapeutic areas. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi Syndrome.

About TYMLOS (abaloparatide) injection

TYMLOS (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

About ATOM Phase 3 Study

The ATOM Phase 3 study is a randomized, double-blind, placebo-controlled study to assess efficacy and safety of abaloparatide injection in 228 men with osteoporosis. The primary endpoint is change in lumbar spine BMD at 12 months compared with placebo, and if successful, will form the basis of a supplemental NDA seeking to expand the use of TYMLOS to treat men with osteoporosis at high risk for fracture.

About the Abaloparatide Transdermal System and wearABLe Phase 3 Study

The abaloparatide transdermal system was developed in a collaboration between Radius and Kindeva Drug Delivery (“Kindeva”) (formerly 3M Drug Delivery Systems) with the application of Kindeva’s innovative microstructured transdermal system technology. The wearABLe study is a pivotal, randomized, open label, active-controlled, bone mineral density (“BMD”) non-inferiority bridging study that will evaluate the efficacy and safety of abaloparatide transdermal system versus TYMLOS (abaloparatide) injection in approximately 500 patients with postmenopausal osteoporosis at high risk for fracture. The primary endpoint of the study is the percentage change in lumbar spine BMD at 12 months.

About Elacestrant (RAD1901) and EMERALD Phase 3 Study

Elacestrant is a selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/ HER2- advanced breast cancer. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients. The study has enrolled 466 patients who have received prior treatment with one or two lines of endocrine therapy, including a cyclin-dependent kinase (CDK) 4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator’s choice of an approved hormonal agent. The primary endpoint of the study is progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. Secondary endpoints include evaluation of overall survival (OS), objective response rate (ORR), and duration of response (DOR).

About Prader-Willi Syndrome

PWS, an orphan disease, is a complex genetic disorder with clinical manifestations on the endocrine and neurological systems. Clinical signs of PWS develop throughout childhood, with hyperphagia and anxiety ranked as the key clinical features seeking medical attention by caregivers of individuals with PWS. Hyperphagia is a relentless, insatiable, pathological drive to eat that requires caregivers to strictly manage access to food through the locking of cabinets and refrigerators. PWS is recognized as the leading genetic cause of life-threatening obesity in children. As life-threatening hyperphagia persists into adulthood, metabolic syndrome expressed through obesity and diabetes can develop and contribute to morbidity and mortality. In addition to food-related behaviors, the behavioral symptoms commonly observed in PWS include high irritability, habitual skin picking, oppositional defiance and cognitive rigidity. There are currently no approved therapies to treat this disorder’s hyperphagia, irritability, or metabolic aspects. In the U.S., PWS occurs in approximately one out of every 15,000 births.

About RAD011

Investigational drug RAD011 is a pharmaceutical-grade synthetic cannabidiol oral solution, manufactured utilizing traditional pharmaceutical manufacturing processes. The product has purity specifications that meet standardized regulatory and quality control requirements and, compared to the process of developing a plant-derived product, the synthetic manufacturing process usually enables increased consistency and greater precision in the product supply. RAD011 has been assessed in over 150 patients across multiple indications and has potential utilization in multiple diseases. Radius is initially targeting Prader-Willi Syndrome (PWS) and anticipates initiating a seamless pivotal Phase 2/3 study for patients with PWS in the fourth quarter of 2021 or first quarter of 2022.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations with respect to the continued commercialization of TYMLOS in the U.S.; our clinical trials, studies and other regulatory initiatives, including the EMERALD Phase 3 clinical trial of elacestrant and our planned seamless Phase 2/3 trial for RAD011; and our goals for the development of our product candidates.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the adverse impact the ongoing COVID-19 pandemic is having and is expected to continue to have on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials, preclinical studies, and employees; quarterly fluctuation in our financial results; our dependence on the success of TYMLOS, and our inability to ensure that TYMLOS will obtain regulatory approval outside the U.S. or be successfully commercialized in any market in which it is approved, including as a result of risk related to coverage, pricing and reimbursement; risks related to competitive products; risks related to our ability to successfully enter into collaboration, partnership, license or similar agreements; risks related to clinical trials, including our reliance on third parties to conduct key portions of our clinical trials and uncertainty that the results of those trials will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates or during commercialization, if approved; risks related to manufacturing, supply and distribution; and the risk of litigation or other challenges regarding our intellectual property rights. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ending December 31, 2020 and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor & Media Relations Contact:

Ethan Holdaway
Email: [email protected]
Phone: (617) 583-2017



Terminix Reports Second-Quarter 2021 Revenue Growth of Five Percent

Terminix Reports Second-Quarter 2021 Revenue Growth of Five Percent

  • Four percent organic revenue growth included double-digit commercial pest growth
  • Net income of $54 million with a margin of 10%
  • Adjusted EBITDA of $123 million with a margin of 22%
  • Repurchased 3.7 million shares for $181 million at an average price of $48.77 per share

MEMPHIS, Tenn.–(BUSINESS WIRE)–
Terminix Global Holdings, Inc. (NYSE: TMX), a leading provider of essential termite and pest management services to residential and commercial customers, today announced unaudited second-quarter 2021 results.

For the second quarter of 2021, the Company reported a year-over-year revenue increase of five percent to $560 million. Income from continuing operations increased year-over-year by $14 million, or 35 percent, to $54 million, or $0.42 per share. Adjusted EBITDA(1) for the quarter increased year-over-year by $4 million, or 3 percent, to $123 million, and Adjusted Net Income(2) increased by $13 million to $66 million, or $0.51 per share.

“Solid revenue growth in commercial and residential pest management highlighted a quarter of continued progress on our strategic initiatives,” said Terminix CEO Brett Ponton. “The double-digit organic revenue growth in our commercial business continues the positive momentum we have seen in the service line as we move beyond the impacts of the COVID-19 pandemic. We delivered strong pricing and customer retention improvements in residential pest management and are making progress on key marketing initiatives that will improve lead generation. I am encouraged by our ability to drive productivity in our fleet and materials cost to help offset expected increases in labor costs due to the more competitive macro labor market.”

“We remain focused on the Terminix Way initiative and customer experience platform as key growth and profitability enablers for the years ahead,” Ponton continued. “Investments in easy-to-use systems will improve lead generation, customer retention, and the customer experience across all touchpoints. Terminix Way will transform the teammate experience with enhanced operating procedures, training curriculums and career paths that will enhance teammate retention and provide the foundation for accelerated growth and improved consistency throughout the organization. I remain confident that we are making the necessary investments in operating capabilities to create a sustainable growth model that will allow us to become the preferred pest management provider in the industry.”

Consolidated Performance

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

$ millions

 

2021

 

2020

 

B/(W)

 

2021

 

2020

 

B/(W)

Revenue

 

$

560

 

 

$

534

 

 

$

26

 

 

$

1,032

 

 

$

990

 

 

$

42

 

YoY growth

 

 

 

 

 

 

 

 

 

 

5

%

 

 

 

 

 

 

 

 

 

 

4

%

Gross Margin

 

 

242

 

 

 

237

 

 

 

6

 

 

 

444

 

 

 

413

 

 

 

31

 

% of revenue

 

 

43.2

%

 

 

44.3

%

 

 

(1.1)

pts

 

 

43.0

%

 

 

41.8

%

 

 

1.3

pts

SG&A

 

 

143

 

 

 

143

 

 

 

1

 

 

 

280

 

 

 

283

 

 

 

3

 

% of revenue

 

 

(25.6)

%

 

 

(26.7)

%

 

 

1.1

pts

 

 

(27.2)

%

 

 

(28.6)

%

 

 

1.4

pts

Income from Continuing Operations before Income Taxes

 

 

73

 

 

 

57

 

 

 

16

 

 

 

110

 

 

 

56

 

 

 

54

 

% of revenue

 

 

13.1

%

 

 

10.7

%

 

 

2.4

pts

 

 

10.7

%

 

 

5.7

%

 

 

5.0

pts

Income from Continuing Operations

 

 

54

 

 

 

40

 

 

 

14

 

 

 

81

 

 

 

41

 

 

 

40

 

% of revenue

 

 

9.6

%

 

 

7.5

%

 

 

2.1

pts

 

 

7.8

%

 

 

4.2

%

 

 

3.7

pts

Net Income

 

 

54

 

 

 

53

 

 

 

1

 

 

 

81

 

 

 

67

 

 

 

14

 

% of revenue

 

 

9.6

%

 

 

9.9

%

 

 

(0.3)

pts

 

 

7.8

%

 

 

6.8

%

 

 

1.0

pts

Adjusted Net Income(2)

 

 

66

 

 

 

53

 

 

 

13

 

 

 

105

 

 

 

64

 

 

 

41

 

% of revenue

 

 

11.7

%

 

 

9.9

%

 

 

1.8

pts

 

 

10.2

%

 

 

6.5

%

 

 

3.7

pts

Adjusted EBITDA(1)

 

 

123

 

 

 

119

 

 

 

4

 

 

 

213

 

 

 

179

 

 

 

34

 

% of revenue

 

 

22.0

%

 

 

22.4

%

 

 

(0.4)

pts

 

 

20.7

%

 

 

18.1

%

 

 

2.6

pts

Net Cash Provided from Operating Activities from Continuing Operations

 

 

76

 

 

 

117

 

 

 

(41)

 

 

 

151

 

 

 

172

 

 

 

(21)

 

Free Cash Flow(3)

 

 

71

 

 

 

112

 

 

 

(41)

 

 

 

139

 

 

 

157

 

 

 

(18)

 

Reconciliations of net income to Adjusted Net Income and Adjusted EBITDA, as well as a reconciliation of Net Cash Provided from Operating Activities from Continuing Operations to Free Cash Flow, are set forth below in this press release.

Second-Quarter Performance

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(In millions)

 

2021

 

2020

 

Growth

 

Organic

 

Acquired

Residential Pest Management

 

$

192

 

$

182

 

$

10

 

5

%

 

$

7

 

4

%

 

$

3

 

1

%

Commercial Pest Management

 

 

141

 

 

124

 

 

17

 

14

%

 

 

13

 

10

%

 

 

4

 

3

%

Termite and Home Services

 

 

193

 

 

196

 

 

(3)

 

(2)

%

 

 

(4)

 

(2)

%

 

 

 

%

Sales of Products and Other

 

 

34

 

 

32

 

 

3

 

8

%

 

 

3

 

8

%

 

 

 

%

Total revenue

 

$

560

 

$

534

 

$

26

 

5

%

 

$

19

 

4

%

 

$

7

 

1

%

Revenue increased five percent over the prior year, including approximately one percent from favorable foreign currency fluctuations. Commercial pest management organic revenue growth(4) of ten percent, including double-digit international growth, was driven by a decrease in temporary cancellations from the prior year and improved price realization. Foreign currency fluctuations contributed approximately $4 million, or three percent, of the commercial pest management organic revenue growth. Residential pest management organic revenue growth of four percent was driven by an improvement in customer retention and improved price realization, offset, in part, by lower one-time sales. Termite and Home Services revenue decreased two percent organically primarily due to an approximately $5 million impact from the change in the timing of revenue recognition in our monthly subscription-based termite offering. Excluding this impact, Termite and Home Service revenue would have increased approximately one percent. Sales of products and other increased eight percent due to prior year COVID-19 pandemic impacts.

Adjusted EBITDA

Adjusted EBITDA was $123 million for the second quarter, a year-over-year increase of $4 million. The impact on Adjusted EBITDA from higher revenue was $13 million. Direct costs, including materials and fleet costs, were $4 million lower year-over-year. These gains were partially offset by a $6 million increase in labor expense, $2 million in investments in the customer experience platform and Terminix Way, higher sales and marketing expense of $3 million, and a $1 million increase in termite damage claims expense, primarily driven by higher cost per non-litigated claim due, in part, to inflationary pressures on building materials and contractor costs.

Liquidity and Free Cash Flow

The Company ended the second quarter with $313 million in available cash and access to $378 million under its revolving credit facility for total liquidity of $691 million. In the second quarter, the Company purchased 3.7 million shares for $181 million at an average price of $48.77 per share. Year-to-date free cash flow was $139 million, with a free cash flow conversion rate(5) of 65 percent. The Company ended the second quarter with a net debt leverage ratio(6) of 1.5 times.

Full-Year 2021 Outlook

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(In millions)

 

Low

 

High

Revenue

 

$

2,025

 

 

$

2,050

 

Growth Rate

 

 

3%

 

 

 

4%

 

Adjusted EBITDA

 

$

380

 

 

$

390

 

Margin

 

 

18.8%

 

 

 

19.0%

 

For the full-year 2021, our outlook remains unchanged with organic revenue growth expected between three and four percent. Residential pest is expected to continue growth from pricing realization. Commercial pest is expected to stabilize to more normalized growth levels than the second quarter as the prior year impact of the COVID-19 pandemic mitigates in the third and fourth quarters. Termite and home services is expected to be negatively impacted by approximately $2 million in the third quarter due to the timing of revenue recognized for our monthly subscription-based termite offering.

Adjusted EBITDA remains between $380 and $390 million and includes the flow through of revenue growth, expected teammate retention pressure from tighter labor markets, increased sales and marketing expense and investments in key operational capabilities.

The timing and frequency of new termite damage claims litigated case filings are difficult to predict. This guidance represents the Company’s best estimate of litigated case filings, but actual pace and volume could differ.

A reconciliation of the forward looking full-year 2021 Adjusted EBITDA outlook to net income is not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation.

Second-Quarter 2021 Earnings Conference Call

The Company will hold a conference call to discuss its financial and operating results at 8 a.m. central time (9 a.m. eastern time) on Thursday, August 5, 2021.

The Company invites all interested parties to join Chief Executive Officer, Brett Ponton, Executive Vice President and Chief Financial Officer, Bob Riesbeck, and Vice President of Investor Relations, FP&A and Treasurer, Jesse Jenkins, for an update on the Company’s operational performance and financial results for the second quarter ended June 30, 2021. Participants may join this conference call by dialing 877.256.3282 (or international participants, +1.212.231.2904). Additionally, the conference call will be available via webcast. A slide presentation highlighting the Company’s results will also be available. To participate via webcast and view the presentation, visit the Company’s investor relations home page at investors.terminix.com.

The call will be available for replay until September 4, 2021. To access the replay of this call, please call 800.633.8284 and enter reservation number 21995995 (international participants: +1.402.977.9140, reservation number 21995995). The webcast will also be available on the company’s investor relations home page.

About Terminix

Terminix Global Holdings (NYSE: TMX) is a leading provider of residential and commercial pest management. The Company provides pest management services and protection against termites, mosquitoes, rodents and other pests. Headquartered in Memphis, Tenn., with more than 11,400 teammates and 2.9 million customers in 24 countries and territories, the Company visits more than 50,000 homes and businesses every day. To learn more about Terminix, visit Terminix.com, or LinkedIn.com/company/terminix.

Information Regarding Forward-Looking Statements

This press release contains forward-looking statements and cautionary statements. Forward-looking statements can be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “seeks,” “aims,” “projects,” “is optimistic,” “intends,” “plans,” “estimates,” “anticipates” or other comparable terms. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control, including, without limitation, the risks and uncertainties discussed in the “Risk Factors” and “Information Regarding Forward-Looking Statements” sections in the Company’s reports filed with the U.S. Securities and Exchange Commission. Such risks, uncertainties and changes in circumstances include, but are not limited to: the impact of reserves attributable to pending Litigated and Non-Litigated Claims for termite damages; future termite damage claim expenses above historical norms remaining within the ringfence estimate; implementation of Mobile Bay Formosan termite settlement remediation measures; the mitigating impact of the Mobile Bay Formosan termite settlement on future litigated termite damage claims; the impact of the COVID-19 pandemic on our operations; lawsuits, enforcement actions and other claims by first parties or governmental authorities; compliance with, or violation of environmental health and safety laws and regulations; weakening general economic conditions; weather conditions and seasonality; the success of our business strategies, and costs associated with restructuring initiatives. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of the market segments in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this press release. The Company assumes no obligation to update the information contained herein, which speaks only as of the date hereof.

Non-GAAP Financial Measures

This press release contains certain non-GAAP financial measures. Non-GAAP measures should not be considered as an alternative to GAAP financial measures. Non-GAAP measures may not be calculated like or comparable to similarly titled measures of other companies. See non-GAAP reconciliations below in this press release for a reconciliation of these measures to the most directly comparable GAAP financial measures. Adjusted EBITDA, Adjusted Net Income, Adjusted earnings per share, free cash flow, free cash flow conversion rate, organic revenue growth and net debt leverage ratio are not measurements of the Company’s financial performance under GAAP and should not be considered as an alternative to net income, net cash provided by operating activities from continuing operations or any other performance or liquidity measures derived in accordance with GAAP. Management uses these non-GAAP financial measures to facilitate operating performance and liquidity comparisons, as applicable, from period to period. We believe these non-GAAP financial measures are useful for investors, analysts and other interested parties as they facilitate company-to-company operating performance and liquidity comparisons, as applicable, by excluding potential differences caused by variations in capital structures, acquisition activity, taxation, the age and book depreciation of facilities and equipment, restructuring initiatives and equity-based, long-term incentive plans.

_______________________________________________

(1) Adjusted EBITDA is defined as net income before: depreciation and amortization expense; acquisition-related costs; Mobile Bay Formosan termite settlement; non-cash stock-based compensation expense; restructuring and other charges; net earnings from discontinued operations; provision for income taxes; and interest expense. The Company’s definition of Adjusted EBITDA may not be comparable to similarly titled measures of other companies.

(2) Adjusted Net Income is defined as net income before: amortization expense; acquisition-related costs; Mobile Bay Formosan termite settlement; restructuring and other charges; net earnings from discontinued operations; and the tax impact of the aforementioned adjustments. The Company’s definition of Adjusted Net Income may not be comparable to similarly titled measures of other companies. Adjusted earnings per share is calculated as Adjusted Net Income divided by the weighted-average diluted common shares outstanding.

(3) Free cash flow is defined as net cash provided from operating activities from continuing operations less property additions.

(4) Organic revenue growth is defined as revenue excluding revenue from acquired customers for 12 months following the acquisition date.

(5) Free cash flow conversion rate is defined as free cash flow divided by Adjusted EBITDA.

(6) Net debt leverage ratio is defined as total debt less cash divided by LTM Adjusted EBITDA. LTM Adjusted EBITDA is calculated as Q2 2021 YTD Adjusted EBITDA ($213 million) plus 2020 Adjusted EBITDA ($345 million) less Q2 2020 YTD Adjusted EBITDA ($179 million).

 

TERMINIX GLOBAL HOLDINGS, INC.

Consolidated Statements of Operations and Comprehensive Income

(In millions, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

 

 

2021

 

2020

 

2021

 

 

2020

 

Revenue

 

$

560

 

 

$

534

 

 

$

1,032

 

 

$

990

 

Cost of services rendered and products sold

 

 

318

 

 

 

297

 

 

 

588

 

 

 

577

 

Selling and administrative expenses

 

 

143

 

 

 

143

 

 

 

280

 

 

 

283

 

Amortization expense

 

 

10

 

 

 

9

 

 

 

19

 

 

 

18

 

Acquisition-related costs

 

 

(1

)

 

 

 

 

 

(1

)

 

 

1

 

Mobile Bay Formosan termite settlement

 

 

4

 

 

 

 

 

 

4

 

 

 

 

Restructuring and other charges

 

 

2

 

 

 

8

 

 

 

9

 

 

 

12

 

Interest expense

 

 

11

 

 

 

22

 

 

 

23

 

 

 

45

 

Interest and net investment income

 

 

(1

)

 

 

(1

)

 

 

(1

)

 

 

(1

)

Income from Continuing Operations before Income Taxes

 

 

73

 

 

 

57

 

 

 

110

 

 

 

56

 

Provision for income taxes

 

 

20

 

 

 

18

 

 

 

31

 

 

 

16

 

Equity in earnings of joint ventures

 

 

1

 

 

 

1

 

 

 

2

 

 

 

1

 

Income from Continuing Operations

 

 

54

 

 

 

40

 

 

 

81

 

 

 

41

 

Net earnings from discontinued operations

 

 

 

 

 

13

 

 

 

 

 

 

26

 

Net Income

 

$

54

 

 

$

53

 

 

$

81

 

 

$

67

 

Total Comprehensive Income

 

$

48

 

 

$

54

 

 

$

97

 

 

$

19

 

Weighted-average common shares outstanding – Basic

 

 

127.4

 

 

 

131.9

 

 

 

129.3

 

 

 

133.4

 

Weighted-average common shares outstanding – Diluted

 

 

127.8

 

 

 

132.0

 

 

 

129.8

 

 

 

133.5

 

Basic Earnings Per Share:

 

 

 

 

 

 

 

 

 

 

 

 

Income from Continuing Operations

 

$

0.42

 

 

$

0.30

 

 

$

0.63

 

 

$

0.31

 

Net earnings from discontinued operations

 

 

 

 

 

0.10

 

 

 

 

 

 

0.19

 

Net Income

 

 

0.42

 

 

 

0.40

 

 

 

0.62

 

 

 

0.50

 

Diluted Earnings Per Share:

 

 

 

 

 

 

 

 

 

 

 

 

Income from Continuing Operations

 

$

0.42

 

 

$

0.30

 

 

$

0.62

 

 

$

0.31

 

Net earnings from discontinued operations

 

 

 

 

 

0.10

 

 

 

 

 

 

0.19

 

Net Income

 

 

0.42

 

 

 

0.40

 

 

 

0.62

 

 

 

0.50

 

 

 

TERMINIX GLOBAL HOLDINGS, INC.

Consolidated Statements of Financial Position

(In millions, except share data)

 

 

 

 

 

 

 

 

 

As of

 

As of

 

 

June 30,

 

December 31,

 

 

2021

 

 

2020

 

Assets:

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

313

 

 

$

615

 

Receivables, less allowances of $27 and $25, respectively

 

 

208

 

 

 

206

 

Inventories

 

 

42

 

 

 

44

 

Prepaid expenses and other assets

 

 

167

 

 

 

145

 

Total Current Assets

 

 

730

 

 

 

1,010

 

Other Assets:

 

 

 

 

 

 

Property and equipment, net

 

 

177

 

 

 

182

 

Operating lease right-of-use assets

 

 

80

 

 

 

80

 

Goodwill

 

 

2,168

 

 

 

2,146

 

Intangible assets, primarily trade names, service marks and trademarks, net

 

 

1,104

 

 

 

1,111

 

Restricted cash

 

 

89

 

 

 

89

 

Notes receivable

 

 

32

 

 

 

31

 

Long-term marketable securities

 

 

15

 

 

 

14

 

Deferred customer acquisition costs

 

 

96

 

 

 

98

 

Other assets

 

 

76

 

 

 

75

 

Total Assets

 

$

4,567

 

 

$

4,837

 

Liabilities and Stockholders’ Equity:

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

Accounts payable

 

$

113

 

 

$

91

 

Accrued liabilities:

 

 

 

 

 

 

Payroll and related expenses

 

 

90

 

 

 

102

 

Self-insured claims and related expenses

 

 

70

 

 

 

76

 

Accrued interest payable

 

 

7

 

 

 

7

 

Other

 

 

100

 

 

 

99

 

Deferred revenue

 

 

110

 

 

 

102

 

Current portion of lease liability

 

 

17

 

 

 

17

 

Current portion of long-term debt

 

 

44

 

 

 

94

 

Total Current Liabilities

 

 

552

 

 

 

588

 

Long-Term Debt

 

 

834

 

 

 

826

 

Other Long-Term Liabilities:

 

 

 

 

 

 

Deferred taxes

 

 

363

 

 

 

346

 

Other long-term obligations, primarily self-insured claims

 

 

215

 

 

 

239

 

Long-term lease liability

 

 

95

 

 

 

96

 

Total Other Long-Term Liabilities

 

 

673

 

 

 

681

 

Commitments and Contingencies

 

 

 

 

 

 

Stockholders’ Equity:

 

 

 

 

 

 

Common stock $0.01 par value (authorized 2,000,000,000 shares with 148,838,068 shares issued and 125,271,848 outstanding at June 30, 2021 and 148,400,384 shares issued and 132,080,845 shares outstanding at December 31, 2020)

 

 

2

 

 

 

2

 

Additional paid-in capital

 

 

2,379

 

 

 

2,359

 

Retained Earnings

 

 

922

 

 

 

841

 

Accumulated other comprehensive loss

 

 

(22

)

 

 

(39

)

Less common stock held in treasury, at cost (23,566,220 shares at June 30, 2021 and 16,319,539 shares at December 31, 2020)

 

 

(773

)

 

 

(423

)

Total Stockholders’ Equity

 

 

2,508

 

 

 

2,741

 

Total Liabilities and Stockholders’ Equity

 

$

4,567

 

 

$

4,837

 

 

 

TERMINIX GLOBAL HOLDINGS, INC.

Consolidated Statements of Cash Flows

(In millions)

 

 

 

 

 

 

 

 

 

Six Months Ended

 

 

June 30,

 

 

2021

 

 

2020

 

Cash and Cash Equivalents and Restricted Cash at Beginning of Period

 

$

704

 

 

$

368

 

Cash Flows from Operating Activities from Continuing Operations:

 

 

 

 

 

 

Net Income

 

 

81

 

 

 

67

 

Adjustments to reconcile net income to net cash provided from operating activities:

 

 

 

 

 

 

Net earnings from discontinued operations

 

 

 

 

 

(26

)

Equity in earnings of joint venture

 

 

(2

)

 

 

(1

)

Depreciation expense

 

 

35

 

 

 

37

 

Amortization expense

 

 

19

 

 

 

18

 

Amortization of debt issuance costs

 

 

1

 

 

 

2

 

Amortization of lease right-of-use assets

 

 

8

 

 

 

9

 

Mobile Bay Formosan termite settlement

 

 

4

 

 

 

 

Deferred income tax provision

 

 

13

 

 

 

 

Stock-based compensation expense

 

 

11

 

 

 

10

 

Restructuring and other charges

 

 

9

 

 

 

12

 

Payments for restructuring and other charges

 

 

(5

)

 

 

(6

)

Acquisition-related costs

 

 

(1

)

 

 

1

 

Payments for acquisition-related costs

 

 

(1

)

 

 

(4

)

Other

 

 

(12

)

 

 

(9

)

Change in working capital, net of acquisitions:

 

 

 

 

 

 

Receivables

 

 

(7

)

 

 

(29

)

Inventories and other current assets

 

 

(25

)

 

 

(6

)

Accounts payable

 

 

23

 

 

 

26

 

Deferred revenue

 

 

8

 

 

 

4

 

Accrued liabilities

 

 

(12

)

 

 

31

 

Accrued interest payable

 

 

 

 

 

(4

)

Current income taxes

 

 

2

 

 

 

40

 

Net Cash Provided from Operating Activities from Continuing Operations

 

 

151

 

 

 

172

 

Cash Flows from Investing Activities from Continuing Operations:

 

 

 

 

 

 

Property additions

 

 

(12

)

 

 

(15

)

Sale of equipment and other assets

 

 

1

 

 

 

 

Business acquisitions, net of cash acquired

 

 

(45

)

 

 

(24

)

Origination of notes receivable

 

 

(34

)

 

 

(20

)

Collections on notes receivable

 

 

33

 

 

 

22

 

Net Cash Used for Investing Activities from Continuing Operations

 

 

(56

)

 

 

(36

)

Cash Flows from Financing Activities from Continuing Operations:

 

 

 

 

 

 

Payments of debt

 

 

(67

)

 

 

(40

)

Repurchase of common stock

 

 

(350

)

 

 

(103

)

Issuance of common stock

 

 

8

 

 

 

3

 

Net Cash Used For Financing Activities from Continuing Operations

 

 

(409

)

 

 

(140

)

Cash Flows from Discontinued Operations:

 

 

 

 

 

 

Cash provided from operating activities

 

 

12

 

 

 

27

 

Net Cash Provided from Discontinued Operations

 

 

12

 

 

 

28

 

Effect of Exchange Rate Changes on Cash

 

 

 

 

 

(1

)

Cash (Decrease) Increase During the Period

 

 

(302

)

 

 

22

 

Cash and Cash Equivalents and Restricted Cash at End of Period

 

$

402

 

 

$

391

 

The following table presents reconciliations of net income to Adjusted Net Income:

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

(In millions)

 

2021

 

2020

 

2021

 

2020

 

Net Income

 

$

54

 

 

$

53

 

 

$

81

 

 

$

67

 

Amortization expense

 

 

10

 

 

 

9

 

 

 

19

 

 

 

18

 

Acquisition-related costs

 

 

(1

)

 

 

 

 

 

(1

)

 

 

1

 

Mobile Bay Formosan termite settlement

 

 

4

 

 

 

 

 

 

4

 

 

 

 

Restructuring and other charges

 

 

2

 

 

 

8

 

 

 

9

 

 

 

12

 

Net earnings from discontinued operations

 

 

 

 

 

(13

)

 

 

 

 

 

(26

)

Tax impact of adjustments

 

 

(4

)

 

 

(4

)

 

 

(8

)

 

 

(8

)

Adjusted Net Income

 

$

66

 

 

$

53

 

 

$

105

 

 

$

64

 

Weighted-average diluted common shares outstanding

 

 

127.8

 

 

 

132.0

 

 

 

129.8

 

 

 

133.5

 

Adjusted earnings per share

 

$

0.51

 

 

$

0.40

 

 

$

0.81

 

 

$

0.48

 

The following table presents reconciliations of net cash provided from operating activities from continuing operations to free cash flow:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

(In millions)

 

2021

 

2020

 

 

2021

 

2020

 

Net Cash Provided from Operating Activities from Continuing Operations

 

$

76

 

 

$

117

 

 

 

$

151

 

 

 

$

172

 

 

Property additions

 

 

(6

)

 

 

(5

)

 

 

 

(12

)

 

 

 

(15

)

 

Free Cash Flow

 

$

71

 

 

$

112

 

 

 

$

139

 

 

 

$

157

 

 

The following table presents reconciliations of net income to Adjusted EBITDA.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

(In millions)

 

2021

 

2020

 

2021

 

2020

Net income

 

$

54

 

$

53

 

$

81

 

$

67

Depreciation and amortization expense

 

 

26

 

 

27

 

 

54

 

 

55

Acquisition-related costs

 

 

(1)

 

 

 

 

(1)

 

 

1

Mobile Bay Formosan termite settlement

 

 

4

 

 

 

 

4

 

 

Non-cash stock-based compensation expense

 

 

5

 

 

5

 

 

11

 

 

10

Restructuring and other charges

 

 

2

 

 

8

 

 

9

 

 

12

Net earnings from discontinued operations

 

 

 

 

(13)

 

 

 

 

(26)

Provision for income taxes

 

 

20

 

 

18

 

 

31

 

 

16

Interest expense

 

 

11

 

 

22

 

 

23

 

 

45

Adjusted EBITDA

 

$

123

 

$

119

 

$

213

 

$

179

 

Investor Relations:

Jesse Jenkins

901.597.8259

[email protected]

Media:

James Robinson

901.597.7521

[email protected]

KEYWORDS: United States North America Tennessee

INDUSTRY KEYWORDS: Home Goods Commercial Building & Real Estate Construction & Property Small Business Professional Services Other Construction & Property Retail Residential Building & Real Estate

MEDIA:

Logo
Logo

Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and six months ended June 30, 2021, prior to the open of the U.S. financial markets on Wednesday, August 11, 2021.

Kamada management will host an investment community conference call on Wednesday, August 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13721962. The call will also be webcast live on the Internet at http://public.viavid.com/index.php?id=145993.

The call will also be archived for 90 days on the Company’s website at www.kamada.com.

About Kamada
Kamada Ltd. (the “Company”) is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company’s two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited (“Takeda”) and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, and a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

CONTACTS:

Chaime Orlev
Chief Financial Officer
[email protected]

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]



WPP 2021 Interim Results

WPP 2021 Interim Results

Strong first half across the business: returned to 2019 levels a year ahead of plan; full-year guidance raised; good progress on transformation; £350 million buyback planned for H2

NEW YORK & LONDON–(BUSINESS WIRE)–
WPP (NYSE: WPP) today reported its 2021 Interim Results.

Key figures – continuing operations

£ million

H1 2021

 

+/(-) %

reported1

 

+/(-) %

LFL2

 

H1 20203

Revenue

6,133

 

9.8

 

16.1

 

5,583

Revenue less pass-through costs

4,899

 

5.0

 

11.0

 

4,668

 

 

 

 

 

Reported:

 

 

 

 

Operating profit/(loss)

484

 

n/m4

 

 

(2,751)

Profit/(loss) before tax

394

 

n/m

 

 

(3,177)

Diluted EPS (p)

20.6

 

n/m

 

 

(262.0)

Dividends per share (p)

12.5

 

25.0

 

 

10.0

 

 

 

 

 

Headline5:

 

 

 

 

Operating profit

590

 

54.4

 

 

382

Operating profit margin

12.1%

 

3.9pt*

 

 

8.2%

Profit before tax

502

 

81.9

 

 

276

Diluted EPS (p)

28.7

 

86.4

 

 

15.4

* Margin points

H1 and Q2 financial highlights

  • H1 reported revenue 9.8%, LFL revenue 16.1% (Q2 26.4%)
  • H1 revenue less pass-through costs 5.0%, LFL revenue less pass-through costs 11.0% (up 0.5% on H1 2019)
  • Q2 LFL revenue less pass-through costs 19.3%: US 12.6%, UK 31.8%, Germany 20.3%, Greater China 1.4%, Australia 8.4%, India 30.0%
  • Q2 LFL revenue less pass-through costs on 2019 1.3%: US 1.8%, UK 1.1%, Germany 6.3%, Greater China -1.7%, Australia -13.6%, India -2.6%
  • Strong new business performance: $2.9 billion net new billings in H1
  • H1 headline operating margin 12.1%, up 3.9 pt on prior year with strong top-line growth supporting significant reinvestment in incentives
  • H1 headline operating margin pre incentives up 7.8 pt to 17.0%
  • Net debt at 30 June 2021 £1.5 billion, down £1.2 billion year-on-year reflecting good working capital management

Strategic progress, shareholder returns and outlook

  • Shifting business mix: growth areas of experience, commerce and technology represented 26% of revenue less pass-through costs in H1
  • Launch of Choreograph, future-ready data and analytics company
  • M&A to simplify and grow: buy-in of WPP AUNZ minorities; technology acquisitions in Brazil and UK; Kantar agreed to acquire Numerator
  • Continued recognition of creativity and effectiveness: most creative company at Cannes, collecting 190 Lions including 12 Grand Prix, 1 Titanium, 28 Gold, 57 Silver and 92 Bronze
  • Industry-leading commitment to net zero carbon emissions across entire supply chain by 2030
  • £248m share buyback in H1, £350m planned for H2; 12.5p 2021 interim dividend declared, +25%
  • Full year 2021 LFL revenue less pass-through costs growth now expected to be 9-10%; headline operating margin towards the upper end of the 13.5-14.0% range

Mark Read, Chief Executive Officer, WPP:

“I’m delighted with our performance in the first six months of the year, at a time when COVID continues to take a toll on many countries. The like-for-like revenue less pass-through costs growth rate of 19.3% in the second quarter is our highest on record, as clients reinvest in marketing, particularly in digital media, ecommerce and marketing technology. We have returned to 2019 levels in 2021, a year ahead of our plan, with good momentum into 2022.

“We’ve also made very good strategic progress. Our recognition as the most awarded company at the 2021 Cannes Lions Festival reflects our investment in creative talent and the strength of our creative work over the past two years. Our focus on data, commerce and technology, through strategic acquisitions, organic investments and the launch of Choreograph, has supported a strong new business performance. Key assignment wins include AstraZeneca, Bumble, JP Morgan Chase and Pernod Ricard.

“In procurement, property and shared services, we are making strong progress as part of our overall transformation programme. We have significantly increased our incentive pools in the first half, to reflect the tremendous contribution of our people in these challenging times, and in line with our intention to reinvest in talent announced at our Capital Markets Day in December 2020.

“We expect our strategy to translate into benefits for all of our stakeholders: a powerful, modern offer to support our clients’ growth; a great place for our people to work; a positive contribution to communities and the environment; and good financial returns for shareholders, with the interim dividend raised 25% and £600 million of share buybacks planned in 2021.”

To access WPP’s 2021 interim results financial tables, please visit: www.wpp.com/investors

First half overview

Market environment

The market recovery in the first half of the year has been much faster than expected. Successful vaccination programmes in our major markets have accelerated the easing of restrictions, stimulating economic activity. As the global recovery gathered pace, GroupM made a significant upward revision of its advertising forecasts, predicting that the global advertising economy will grow by 19% in 2021 (excluding US political advertising).

Much of this growth is expected to be captured by digital media, as the underlying trends accelerated by the pandemic, such as the shift to ecommerce and digitisation of media, have continued in the first half of 2021. GroupM forecasts show digital media spend increasing by 26% in 2021, a major uplift from the 15% estimated in December 2020. Spend on television advertising is expected to grow by 9%, as marketers continue to rely on the medium’s reach advantage to reinforce the strength of their brands. Most other advertising channels are expected to stabilise or grow during 2021, aside from magazines and newspapers where spend is expected to decline.

The recovery has been broad-based across all major markets as economies have begun to stabilise, supported by government stimulus and vaccination roll-outs. Based on GroupM forecasts, advertising spend in the UK will grow by 24% in 2021 driven by the economic recovery. Better than 20% growth in advertising spend is also forecast in Brazil and China. The US advertising market is expected to grow by 17% in 2021, or 22% excluding political spend.

Performance and progress

Revenue in the first half was £6.1 billion, up 9.8% from £5.6 billion in the first half of 2020, and up 16.1% like-for-like. Revenue less pass-through costs was £4.9 billion, up 5.0% from £4.7 billion in the first half of 2020, and up 11.0% like-for-like.

We have seen a strong recovery in the first half of the year, with LFL growth in revenue less pass-through costs across all sectors and most major markets. On a two-year basis we are 0.5% ahead of 2019 performance for the first half in terms of LFL revenue less pass-through costs, having been slightly below 2019 levels in the first quarter of the year.

The nature of our work for clients has continued to evolve. We have seen very strong demand from clients for commerce services. GroupM commerce billings increased 61% year-on-year in the first half. Our expertise in commerce was recognised in March, when Forrester named WPP a Leader among commerce services providers in the Forrester Wave™: Commerce Services, Q1 2021 report. Further highlighting our pivot to digital, GroupM’s proportion of digital billings has increased from 41% in 2020 to 43% in the first half of 2021.

Our PR business has performed strongly (LFL revenue less pass-through costs +7.4%), as WPP agencies remain a critical partner and advisor to our clients. We have seen high demand for purpose-related communications, as our clients have sought advice on how to engage with their own stakeholders on sustainability issues, and we see this as a significant opportunity for growth.

In terms of client sector performance, we have seen a sustained strong performance from our clients in the consumer packaged goods, technology and healthcare & pharma sectors, which together represent around 54% of our revenue less pass-through costs for designated clients. In the first half these sectors saw LFL revenue less pass-through costs growth of 11.3%, 14.5% and 13.4% respectively. Compared to 2019, their growth rates were 7.2%, 12.7% and 10.8%.

We have had a good performance in terms of new business, with $2.9 billion of net new business billings won in the first half. The performance of our integrated agencies, the strength and scale of our global footprint and the collaboration between agencies have continued to attract and retain clients. Key assignment wins include AstraZeneca, Bumble, Hyatt, JP Morgan Chase, L’Oréal, Pernod Ricard and Sam’s Club, and key retentions include the US Navy.

During the period, we continued to invest in strategically important areas. We announced the acquisitions of DTI, a digital innovation and software engineering business in Brazil, and NN4M, a leading mobile commerce partner for global brands. In addition, our 40% associate Kantar agreed to acquire Numerator, a technology-driven consumer and market intelligence company.

Our commitment to creativity is now being reflected more widely in our work and awards. WPP was named the most creative company of the year at the Cannes Lions International Festival of Creativity in June, reflecting the investments we have made in creativity and the strength of our talent. Our agencies collected a total of 190 Lions, including a Titanium Lion and 12 Grand Prix, with winners representing 38 different countries. We announced the appointment of Rob Reilly as Global Chief Creative Officer in January 2021, reinforcing our commitment to drive creativity across WPP.

We are making good progress on our transformation programme, as we lay the foundations for realising structural efficiencies in a number of areas. In property, where our campus strategy is well-advanced, we are on track to occupy 32 campuses by the end of 2021, with new cities this year including Detroit, Jakarta and Milan. The adoption of more hybrid working practices will further amplify the benefits of our campuses, and total establishment costs are expected to be below 6% of revenue less pass-through costs this year. In shared services, we are establishing global and regional hubs, and have already deployed units from four markets into these locations. In Enterprise IT, our benchmarking work has identified significant opportunities as we develop plans to reduce the gap between our cost of IT and the industry benchmark. In procurement, we are pursuing an extensive programme to consolidate our supplier base and re-tender existing supply arrangements to tackle the significant opportunities within our £2 billion of annual indirect spend.

We have also made further structural and organisational changes which simplify WPP and improve the way we go to market and serve clients. We have established Choreograph, a new global data company, bringing together the specialist data units of GroupM and Wunderman Thompson into a single company with global reach, accessible to all WPP clients and companies, and recently announced the appointment of Brendan Moorcroft as CEO. In addition, we have combined separate operations into a single brand research and analytics platform under BAV, creating the leading source of brand analytics on over 60,000 brands worldwide. This will enable us to better integrate brand data into our data analytics offer across WPP companies. Finally, we completed the transaction to take 100% ownership of WPP AUNZ, further simplifying the group structure.

Purpose and ESG

Environmental, social and governance issues are an increasingly important topic for all our stakeholders, particularly our clients and our people. WPP is at the heart of many of the pressing issues that we face as a society and the actions and judgements we make as a business are critically important.

WPP’s purpose is to use the power of creativity to build better futures for our people, our planet, our clients and our communities. In June, we hosted an ESG event for stakeholders, to set out our commitments and highlight the progress we have made across the four pillars of our purpose statement.

Putting purpose at the heart of our business makes WPP a more attractive employer for our people. In order to attract, retain and grow top talent we have continued to invest in our people strategy to ensure WPP is an employer of choice for all. This year we launched our first quarterly Pulse survey, an employee listening tool designed to better understand the sentiment of our people and highlight the areas we need to focus on. WPP is committed to real progress on diversity, equity and inclusion, and this year for the first time we have incorporated diversity and sustainability metrics into the compensation schemes for senior leaders. We have also increased our incentive pools, as part of our plan to reinvest savings in attracting and retaining talent.

Earlier this year, we announced our new commitments to reduce carbon emissions from our own operations to net zero by 2025 and across our supply chain by 2030. Our net zero pledges are backed by equally ambitious science-based reduction targets, which have been verified by the Science-Based Targets initiative. We have committed to reducing our absolute Scope 1 and 2 emissions by at least 84% by 2025 and reduce Scope 3 emissions by at least 50% by 2030, both from a 2019 base year.

Many of our clients are making great progress on reducing their own emissions and we will continue to support them to reach their targets. We have been recognised for our creativity in ESG-related work at the Cannes Lions International Festival of Creativity including a Titanium Grand Prix for Telenor work by Ogilvy in the mobile category, using technology to alleviate inequalities in Pakistan. In addition we won two design Grand Prix for AKQA’s work with H&M pioneering an in-store recycling system and Superunion’s work with Notpla, designing a sustainable alternative to plastic packaging.

WPP’s global scale and reach puts us in a unique position to build global partnerships and make a positive contribution to the communities in which we operate. This year, through the WPP India Foundation we set up a COVID relief fund, providing ambulances on call, organising oxygen concentrators, and supporting a vaccination drive for all our people and their families across India.

2021 guidance

Performance in the first half of 2021 has been strong, and we are confident of further good growth in the second half. As a result, we are raising our guidance for 2021 as follows:

  • Organic growth (defined as like-for-like revenue less pass-through costs growth) of 9-10% (previously mid-single-digits %), returning to 2019 levels a year ahead of plan
  • Headline operating margin towards the upper end of the range of 13.5-14.0%
  • Capex £450-500 million

In addition, our current projections for foreign exchange movements imply 4-5 percentage point drag to reported revenue less pass-through costs from the strength of sterling year-on-year. We also anticipate a net working capital outflow for 2021 of £200-300 million, reflecting some normalisation from the very strong position at the end of 2020.

Medium-term guidance

At our Capital Markets Day in December 2020, we set out our new medium-term financial targets that will allow us to invest in talent, incentives and technology, improve our competitive position and deliver sustainable long-term growth. These were:

  • Recovery to 2019 revenue less pass-through costs levels by 2022
  • 3-4% annual growth in revenue less pass-through costs from 2023, including M&A benefit of 0.5-1.0% annually
  • 15.5-16.0% headline operating margin in 2023
  • Dividend: intention to grow annually with a pay-out ratio around 40% of headline diluted EPS
  • Average net debt/EBITDA maintained in the range 1.5-1.75x

We now expect to recover to 2019 levels of revenue less pass-through costs on a like-for-like basis in the current year. The rest of these targets remain unchanged.

Financial results

Unaudited headline income statement:

Six months ended (£ million)

 

30 June

2021

 

 

30 June

2020

 

+/(-) %

reported

 

+/(-) % LFL

Continuing operations

 

 

 

 

 

 

 

Revenue

6,133

 

5,583

 

9.8

 

16.1

Revenue less pass-through costs

4,899

 

4,668

 

5.0

 

11.0

Operating profit

590

 

382

 

54.4

 

 

Operating margin %

12.1%

 

8.2%

 

3.9pt

 

 

Income from associates

29

 

 

 

 

PBIT

619

 

382

 

62.0

 

 

Net finance costs

(117)

 

(106)

 

(10.4)

 

 

Profit before tax

502

 

276

 

81.9

 

 

Tax

(115)

 

(64)

 

(78.9)

 

 

Profit after tax

387

 

212

 

82.8

 

 

Non-controlling interests

(34)

 

(21)

 

(64.0)

 

 

Profit attributable to shareholders

353

 

191

 

85.0

 

 

Diluted EPS

28.7p

 

15.4p

 

86.4

 

 

Reconciliation of operating profit/(loss) to headline operating profit:

Six months ended (£ million)

30 June 2021

30 June 20206

Continuing operations

 

 

Operating profit/(loss)

484

 

(2,751)

Amortisation and impairment of acquired intangible assets

30

 

53

Goodwill impairment

 

2,813

Losses/(gains) on disposal of investments and subsidiaries

1

 

(16)

Investment and other write-downs

 

226

Litigation settlement

22

 

Restructuring and transformation costs

34

 

18

Restructuring costs in relation to COVID-19

19

 

39

Headline operating profit

590

 

382

Reported billings were £23.4 billion, up 12.2%, and up 19.3% like-for-like.

Reported revenue from continuing operations was up 9.8% at £6.1 billion. Revenue on a constant currency basis was up 15.8% compared with last year. Net changes from acquisitions and disposals had a negative impact of 0.3% on growth, leading to a like-for-like performance, excluding the impact of currency and acquisitions, of 16.1%.

Reported revenue less pass-through costs was up 5.0%, and up 10.8% on a constant currency basis. Excluding the impact of acquisitions and disposals, like-for-like growth was 11.0%. In the second quarter, like-for-like revenue less pass-through costs was up 19.3%.

Regional review

Revenue analysis

 

Q2

 

H1

 

£m

 

+/(-) %

reported

 

+/(-) %

LFL

 

£m

 

+/(-) %

reported

 

+/(-) %

LFL

N. America

1,121

 

4.2

 

16.7

 

2,184

 

0.3

 

10.2

United Kingdom

493

 

42.2

 

40.5

 

927

 

22.4

 

21.7

W Cont. Europe

728

 

37.1

 

41.1

 

1,341

 

22.7

 

23.5

AP, LA, AME, CEE7

893

 

14.2

 

22.7

 

1,681

 

8.1

 

16.0

Total Group

3,235

 

18.3

 

26.4

 

6,133

 

9.8

 

16.1

Revenue less pass-through costs analysis

 

Q2

 

H1

 

£m

+/(-) %

reported

+/(-) %

LFL

 

£m

+/(-) %

reported

+/(-) %

LFL

N. America

931

 

1.5

13.7

 

1,817

 

(2.1)

 

7.5

United Kingdom

359

 

31.7

31.8

 

680

 

16.1

 

16.9

W Cont. Europe

559

 

23.4

27.1

 

1,050

 

14.2

 

15.0

AP, LA, AME, CEE

716

 

8.8

16.1

 

1,352

 

3.5

 

10.5

Total Group

2,565

 

11.5

19.3

 

4,899

 

5.0

 

11.0

Headline operating profit analysis

£ million

2021

% margin*

2020

% margin*

N. America

271

14.9%

215

11.6%

United Kingdom

83

12.3%

35

6.0%

W Cont. Europe

104

9.9%

44

4.8%

AP, LA, AME, CEE

132

9.7%

88

6.7%

Total Group

590

12.1%

382

8.2%

* Headline operating profit as a percentage of revenue less pass-through costs

North America like-for-like revenue less pass-through costs was up 7.5% in the first half and up 13.7% in the second quarter. On a two-year basis, North America was up 0.9% like-for-like for the first half, with an improving trend in the second quarter. VMLY&R was consistently strong throughout the first half, and GroupM and Ogilvy led the recovery in the second quarter.

United Kingdom like-for-like revenue less pass-through costs was up 16.9% in the first half and up 31.8% in the second quarter. On a two-year basis, the UK was up 0.3% like-for-like for the first half, returning to growth in the second quarter. Of our major agencies, GroupM and AKQA Group showed the biggest improvements in the two-year trend in the second quarter.

Western Continental Europe like-for-like revenue less pass-through costs was up 15.0% in the first half and up 27.1% in the second quarter. We saw a strong performance in Germany, and Italy returned to two-year growth in the second quarter, but France and Spain are yet to recover to 2019 levels.

In Asia Pacific, Latin America, Africa & the Middle East and Central & Eastern Europe, like-for-like revenue less pass-through costs was up 10.5% in the first half and up 16.1% in the second quarter. All regions grew strongly, with Latin America the best-performing, followed by Central & Eastern Europe.

Business sector review

Revenue analysis8

 

Q2

 

H1

 

£m

+/(-) %

reported

+/(-) %

LFL

 

£m

+/(-) %

reported

+/(-) %

LFL

Global Int. Agencies

2,734

17.6

26.4

 

5,170

9.4

16.0

Public Relations

236

5.4

14.1

 

450

0.7

7.5

Specialist Agencies

265

42.1

40.6

 

513

24.9

25.8

Total Group

3,235

18.3

26.4

 

6,133

9.8

16.1

Revenue less pass-through costs analysis

 

Q2

 

H1

 

£m

+/(-) %

reported

+/(-) %

LFL

 

£m

+/(-) %

reported

+/(-) %

LFL

Global Int. Agencies

2,135

10.8

19.2

 

4,069

4.4

10.9

Public Relations

224

4.3

12.9

 

429

0.7

7.4

Specialist Agencies

206

28.6

27.8

 

401

16.1

17.1

Total Group

2,565

11.5

19.3

 

4,899

5.0

11.0

 

Headline operating profit analysis

£ million

2021

% margin*

2020

% margin*

Global Int. Agencies

483

11.9%

282

7.2%

Public Relations

63

14.8%

72

16.9%

Specialist Agencies

44

11.0%

28

8.1%

Total Group

590

12.1%

382

8.2%

* Headline operating profit as a percentage of revenue less pass-through costs

Global Integrated Agencies like-for-like revenue less pass-through costs was up 10.9% in the first half and up 19.2% in the second quarter. GroupM, representing 36% of revenue less pass-through costs, was the strongest performer, up 17.0% like-for-like in the half and up 28.6% in the second quarter. VMLY&R also recorded double-digit growth for the first half, and both businesses recorded encouraging two-year growth. Wunderman Thompson, Ogilvy and AKQA Group all showed a strong recovery in the second quarter.

Public Relations like-for-like revenue less pass-through costs was up 7.4% in the first half and up 12.9% in the second quarter. All parts of the business grew double-digits like-for-like in the second quarter, with Finsbury Glover Hering being the strongest performer.

Specialist Agencies like-for-like revenue less pass-through costs was up 17.1% in the first half and up 27.8% in the second quarter. We saw a very strong recovery in all our brand consulting businesses, with resurgent demand for our services. CMI, our specialist healthcare media business, also continued to perform well.

Operating profitability

Reported profit before tax was £394 million, compared to a loss of £3,177 million in the prior period, principally reflecting the £2.8 billion of impairment charges and £57 million of restructuring and transformation costs in the prior period (see table on page 8).

Reported profit after tax was £287 million compared to a loss last year of £3,188 million.

Headline EBITDA (including IFRS 16 depreciation) for the first half was up 45.8% to £699 million, and up 57.6% in constant currency. Headline operating profit was up 54.4% to £590 million. The strong improvement in profitability year-on-year reflects the recovery in revenue less pass-through costs after the significant impact of COVID-19 in the comparable period.

Headline operating margin was up 390 basis points to 12.1%. Total operating costs were up 0.5% to £4.3 billion. Staff costs, excluding incentives, were down 1.6% year-on-year to £3.2 billion, reflecting lower headcount. Establishment costs were down 15.8% at £265 million as we continued to benefit from our campus roll-out. IT costs were up 1.1% at £277 million and other operating expenses were down 13.4% at £242 million. Personal costs fell 40.7% to £52 million, reflecting very low travel costs. Excluding incentive payments as outlined below, operating costs were down 4.1% year-on-year.

The Group’s headline operating margin is after charging £15 million of severance costs, compared with £19 million in the first half of 2020 and £244 million of incentive payments, compared to £48 million in the first half of 2020. Excluding incentive payments, headline operating margin improved by 780 basis points to 17.0%.

On a like-for-like basis, the average number of people in the Group in the first half was 102,000 compared to 105,000 in the first half of 2020. The total number of people as at 30 June 2021 was 104,000 compared to 102,000 as at 30 June 2020.

Exceptional items

The Group incurred exceptional items of £107 million in the first half of 2021, mainly relating to restructuring and transformation costs and the amortisation and impairment of acquired intangibles, partially offset by the Group’s share of gains in relation to a disposal made by Kantar. This compares with a net exceptional loss in the first half of 2020 of £3.1 billion, which included impairments of £2.8 billion.

Interest and taxes

Net finance costs (excluding the revaluation of financial instruments) were £117 million, an increase of £11 million year-on-year, with the full impact of the coupons on the bonds issued in May 2020 offset by lower average net debt and foreign exchange movements.

The headline tax rate (excluding associate income) was 24.1% (2020: 23.1%) and on reported profit before tax was 27.2% (2020: -0.3%), with the difference in the reported tax rate in 2021 principally due to impairments in 2020. Given the Group’s geographic mix of profits and the changing international tax environment, the tax rate is expected to increase slightly over the next few years.

Earnings and dividend

Headline profit before tax was up 81.9% to £502 million.

Profits attributable to share owners were £253 million, compared to a loss of £3.2 billion in the prior period.

Headline diluted earnings per share from continuing operations rose by 86.4% to 28.7p. Reported diluted earnings per share, on the same basis, was 20.6p, compared to a loss per share of 262.0p in the prior period.

For 2021, the Board is declaring an interim dividend of 12.5p, an increase of 25% year-on-year. The record date for the interim dividend is 15 October 2021, and the dividend will be payable on 1 November 2021.

Further details of WPP’s financial performance are provided in Appendix 1.

Cash flow highlights

Six months ended (£ million)

30 June 2021

30 June 20209

Operating profit/(loss) of continuing and discontinued operations

484

(2,740)

Depreciation and amortisation

250

306

Impairments and investment write-downs

8

3,039

Lease payments (inc interest)

(202)

(203)

Non-cash compensation

44

31

Net interest paid

(65)

(32)

Tax paid

(163)

(201)

Capex

(138)

(141)

Earnout payments

(14)

(88)

Other

(44)

(45)

Trade working capital

(464)

(456)

Other receivables, payables and provisions

(41)

(295)

Free cash flow

(345)

(825)

Disposal proceeds

43

207

Net initial acquisition payments

(252)

(46)

Share purchases

(298)

(286)

Net cash flow

(852)

(950)

 

Net cash outflow for the first half was £852 million, compared to £950 million in the first half of 2020. The main drivers of the cash flow performance year-on-year were the higher operating profit and the improved working capital performance year-on-year, offset by higher consideration for acquisitions (relating mainly to the buy-in of the WPP AUNZ minorities and the equity contribution to Kantar’s acquisition of Numerator), lower net disposal proceeds and the £298 million of share purchases in the first half. A summary of the Group’s unaudited cash flow statement and notes for the six months to 30 June 2021 is provided in Appendix 1.

Balance sheet highlights

As at 30 June 2021 we had cash of £3.3 billion and total liquidity, including undrawn credit facilities, of £5.2 billion. Average net debt in the first half was £1.5 billion, compared to £2.5 billion in the prior period, at 2021 exchange rates. On 30 June 2021 net debt was £1.5 billion, against £2.7 billion on 30 June 2020, a reduction of £1.2 billion, or a reduction of £1.1 billion at 2021 exchange rates.

During the period, we converted the majority of our cash pool arrangements to zero-balancing cash pools, whereby the cash and overdrafts within these cash pools are physically swept to the header accounts on a daily basis, resulting in a reduction of the large gross cash and overdraft positions at 31 December 2020.

We spent £298 million on share purchases in the first half of the year, of which £248 million related to share buybacks.

Our bond portfolio at 30 June 2021 had an average maturity of 6.9 years. In June 2021 we served notice to repay the $500 million 3.625% September 2022 bond in July 2021. There are no further maturities until 2022.

The average net debt to EBITDA ratio in the 12 months to 30 June 2021 is 1.07x, which excludes the impact of IFRS 16. We also expect to end the year below our target leverage range of average net debt/EBITDA of 1.5-1.75x.

A summary of the Group’s unaudited balance sheet and notes as at 30 June 2021 is provided in Appendix 1.

________________________________

1 Percentage change in reported sterling.

2 Like-for-like growth at constant currency exchange rates and excluding the effects of acquisitions and disposals.

3 Prior year figures have been restated as described in note 2 of Appendix 1.

4 Not meaningful.

5 In this press release not all of the figures and ratios used are readily available from the unaudited interim results included in Appendix 1. Management believes these non-GAAP measures, including constant currency and like-for-like growth, revenue less pass-through costs and headline profit measures, are both useful and necessary to better understand the Group’s results. Where required, details of how these have been arrived at are shown in Appendix 2.

6 Prior year figures have been restated as described in note 2 of Appendix 1.

7 Asia Pacific, Latin America, Africa & Middle East and Central & Eastern Europe.

8 AKQA, Geometry, GTB and International Healthcare have been reassigned from Specialist Agencies to Global Integrated Agencies from Q1 2021. 2020 figures have been restated to reflect this change.

9 Prior year figures have been restated as described in note 2 of Appendix 1.

Investors and analysts

Peregrine Riviere +44 7909 907193

Caitlin Holt +44 7392 280178

Fran Butera (US) +1 914 484 1198

Media

Chris Wade +44 20 7282 4600

Richard Oldworth, +44 7710 130 634

Buchanan Communications +44 20 7466 5000

wpp.com/investors

KEYWORDS: Europe United States United Kingdom North America New York

INDUSTRY KEYWORDS: Other Communications Finance Public Relations/Investor Relations Marketing Advertising Banking Communications Professional Services

MEDIA:

Logo
Logo

Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates


2Q21 Total Galafold




®




(migalastat) Revenue of $77.4M, a 24% increase over 2Q20


On-Track to Achieve Revenue Guidance of $300M-$315M


Completed the Rolling BLA and NDA Submissions to the U.S. FDA for AT-GAA in Pompe Disease


Positive EMA Rapporteur and Co-Rapporteur Meeting


Support the MAA Submissions for AT-GAA; Global Submissions On-Track in 2021


Conference Call and Webcast Today at 8:30 a.m. ET

PHILADELPHIA, Aug. 05, 2021 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the quarter ended June 30, 2021.

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “Throughout this year and into the third quarter, the global Amicus team has continued to advance our mission for patients and made significant strides towards achieving our 2021 strategic priorities, including continued commercial execution of Galafold, the completion of our rolling BLA submission with the U.S. FDA and progression of additional global regulatory work for AT-GAA, as well as advancing our industry-leading gene therapy pipeline. Through our efforts, we remain well positioned to deliver on our mission for patients and shareholders, and to continue building Amicus into a leading global rare disease biotechnology company. We are especially excited for and confident in our Pompe program now moving through regulatory reviews around the world and hopeful that it will reach many more people living with Pompe disease as soon as possible.”


Corporate Highlights

  • Global revenue for Galafold

    ®

    (migalastat) in the second quarter of 2021 reached $77.4 million, representing a year-over-year increase of 24.0% from total revenue of $62.4 million in the second quarter of 2020. Second quarter total revenue benefited from a positive currency impact of $4.3 million. On a constant currency basis, second quarter total revenue was $73.1 million, a growth of 17.2% measured at constant currency exchange rates.

  • Galafold EU label expanded following the European Commission approval for use in adolescents. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease aged 12 to <16 years weighing ≥ 45 kg and who have an amenable mutation.

  • Rolling Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat have been submitted to the U.S. Food and Drug Administration (FDA).

  • In the European Union, following a positive rapporteur and co-rapporteur meeting, regulators are supportive of Marketing Authorization Application (MAA) submissions for AT-GAA in the second half of this year.

  • AT-GAA granted positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA). The MHRA’s positive scientific opinion recognizes the high unmet medical need and permits eligible adults living with Late-Onset Pompe disease (LOPD) who have received alglucosidase alfa for at least 2 years to switch and have access to AT-GAA prior to marketing authorization in the U.K.

  • Clinical Batten gene therapy programs continue to advance. The Company continues to follow the first 13 patients with CLN6 and the 4 patients with CLN3 in their respective Phase 1/2 studies. Focus remains on progressing manufacturing, clinical and regulatory activities to enable next clinical studies.

  • Cash position sufficient to achieve self-sustainability without the need for any future dilutive financings. The Company continues to carefully manage expenses and investments, while executing on the Galafold launch, proceeding with AT-GAA global regulatory submissions and advancing development programs.


Second Quarter 2021 Financial Results

  • Total revenue in the second quarter of 2021 was $77.4 million, a year-over-year increase of 24.0% from total revenue of $62.4 million in the second quarter of 2020. On a constant currency basis, second quarter 2021 total revenue was $73.1 million, representing operational revenue growth measured at constant currency exchange rates of 17.2%. Reported revenue was aided by a positive currency impact of $4.3 million, or 6.8%.
  • Cash, cash equivalents, and marketable securities totaled $383.1 million at June 30, 2021, compared to $483.3 million at December 31, 2020.
  • Total GAAP operating expenses of $107.9 million for the second quarter of 2021 increased as compared to $107.0 million for the second quarter 2020.
  • Total non-GAAP operating expenses of $93.5 million for the second quarter of 2021 decreased as compared to $95.9 million in the second quarter of 2020, reflecting the timing of investments in our pipeline.1
  • Net loss was $51.2 million, or $0.19 per share, compared to a net loss of $52.5 million, or $0.20 per share, for the second quarter 2020.

1 Full reconciliation of GAAP results to the Company’s non-GAAP adjusted measures for all reporting periods appear in the tables to this press release.


2021 Financial Guidance

  • For the full-year 2021, the Company anticipates total Galafold revenue of $300 million to $315 million. Double-digit revenue growth in 2021 is expected to be driven by continued operational growth and commercial execution across all major markets, including the U.S., EU, U.K. and Japan.
  • Non-GAAP operating expense guidance for the full-year 2021 is $410 million to $420 million, driven by continued investment in the global Galafold launch, AT-GAA clinical studies and pre-launch activities, and advancing our gene therapy pipeline.2
  • Based on current operating models, the Company believes that the current cash position and expected future revenues are sufficient to fund the Company’s operations and ongoing research programs through to self-sustainability.

2 A reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure.


2021 Milestones by Program

Galafold (migalastat) Oral Precision Medicine for Fabry Disease

  • Continue revenue growth in 2021
  • EU label expanded to cover adolescent population
  • Continue geographic expansion
  • Registry and other Phase 4 studies

AT-GAA for Pompe Disease

  • Completed the BLA and NDA submissions in 3Q21; EU MAA submissions to be completed in 2H2021
  • Ongoing supportive studies, including pediatric and extension studies

Gene Therapy Portfolio

  • Advance manufacturing activities and regulatory discussions for the CLN6 Batten disease gene therapy program to enable dosing of additional patients with GMP clinical grade material
  • Reported initial data from the CLN3 Batten disease gene therapy Phase 1/2 study; advance manufacturing activities and regulatory discussions to enable dosing additional patients with GMP clinical-grade material
  • Continue to progress IND-enabling work in both Pompe and Fabry gene therapies
  • Disclose additional preclinical data and potential IND candidate declarations across multiple preclinical programs
  • Manufacturing advancements and updates across the portfolio



Conference Call and Webcast

Amicus Therapeutics will host a conference call and audio webcast today, August 5, 2021 at 8:30 a.m. ET to discuss the second quarter 2021 financial results and corporate updates. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 7374935.

A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. A replay of the call will be available for seven days beginning at 11:30 a.m. ET on August 5, 2021. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 7374935.


About Galafold

 

Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in over 40 countries around the world, including the U.S., EU, U.K., Japan and others.

U.S. INDICATIONS AND USAGE

Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

U.S. IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.

USE IN SPECIFIC POPULATIONS

There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf.


EU Important Safety Information


Treatment with Galafold should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. Galafold is not recommended for use in patients with a nonamenable mutation.

  • Galafold is not intended for concomitant use with enzyme replacement therapy.
  • Galafold is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m2). The safety and efficacy of Galafold in children less than 12 years of age have not yet been established. No data are available.
  • No dosage adjustments are required in patients with hepatic impairment or in the elderly population.
  • There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.
  • While taking Galafold, effective birth control should be used. It is not known whether Galafold is excreted in human milk.
  • Contraindications to Galafold include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION.
  • Galafold 123 mg capsules are not for children (≥12 years) weighing less than 45 kg.
  • It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on Galafold or switched to Galafold.
  • OVERDOSE: General medical care is recommended in the case of Galafold overdose.
  • The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received Galafold. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS.
  • Call your doctor for medical advice about side effects.

For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu.


About Amicus Therapeutics


Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.


Non-GAAP Financial Measures


In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. Full reconciliations of GAAP results to the comparable non-GAAP measures for the reported periods appear in the financial tables section of this press release. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.



Forward-Looking Statements



This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, and revenue goals, including as they are impacted by COVID-19 related disruption, are based on current information. The potential impact on operations and/or revenue from the COVID-19 pandemic is inherently unknown and cannot be predicted with confidence and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chain disruptions and limitations on patient access to commercial or clinical product or to treatment sites. In addition to the impact of the COVID-19 pandemic, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe, UK, Japan, the US and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies, commercialization and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding corporate financial guidance and financial goals and the attainment of such goals and statements regarding projections of the Company’s revenue and cash position, actual results may differ based on market factors and the Company’s ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report 10-Q for the quarter ended June 30, 2021, to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.


CONTACTS:

Investors:

Andrew Faughnan
Executive Director, Investor Relations
[email protected]
(609) 662-3809

Media:

Diana Moore
Head of Global Corporate Communications
[email protected]
(609) 662-5079

FOLD–G

TABLE 1

Amicus Therapeutics, Inc.

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

  Three Months Ended June 30,   Six Months Ended June 30,
  2021   2020   2021   2020
Net product sales $ 77,413       $ 62,353       $ 143,815       $ 122,878    
Cost of goods sold 8,380       6,676       14,919       13,228    
Gross profit 69,033       55,677       128,896       109,650    
Operating expenses:              
Research and development 63,003       69,611       127,120       158,731    
Selling, general, and administrative 42,276       34,657       89,002       74,872    
Changes in fair value of contingent consideration payable 1,021       715       1,492       1,646    
Depreciation and amortization 1,567       2,039       3,171       3,803    
Total operating expenses 107,867       107,022       220,785       239,052    
Loss from operations (38,834 )     (51,345 )     (91,889 )     (129,402 )  
Other income (expense):              
Interest income 50       865       215       2,380    
Interest expense (8,150 )     (3,635 )     (16,142 )     (7,364 )  
Other expense 234       5,326       (2,966 )     (2,990 )  
Loss before income tax (46,700 )     (48,789 )     (110,782 )     (137,376 )  
Income tax benefit (expense) (4,525 )     (3,703 )     (6,107 )     (4,064 )  
Net loss attributable to common stockholders $ (51,225 )     $ (52,492 )     $ (116,889 )     $ (141,440 )  
Net loss attributable to common stockholders per common share — basic and diluted $ (0.19 )     $ (0.20 )     $ (0.44 )     $ (0.55 )  
Weighted-average common shares outstanding — basic and diluted 266,398,516       257,973,329       265,384,865       257,548,623    



TABLE 2

Amicus Therapeutics, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

  June 30,

2021
  December 31,
2020
   
Assets          
Current assets:          
Cash and cash equivalents $ 176,538       $ 163,240    
Investments in marketable securities 206,530       320,029      
Accounts receivable 49,172       46,923      
Inventories 24,086       19,556      
Prepaid expenses and other current assets 24,176       29,721      
Total current assets 480,502       579,469      
Operating lease right-of-use assets, less accumulated amortization of $8,150 and $7,574 at June 30, 2021 and December 31, 2020, respectively 22,028       23,296      
Property and equipment, less accumulated depreciation of $17,410 and $14,487 at June 30, 2021 and December 31, 2020, respectively 42,365       43,863      
In-process research & development 23,000       23,000      
Goodwill 197,797       197,797      
Other non-current assets 21,200       19,095      
Total Assets $ 786,892       $ 886,520    
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable $ 13,762       $ 17,063    
Accrued expenses and other current liabilities 71,325       96,841      
Contingent consideration payable 19,800       8,900      
Operating lease liabilities 7,106       6,872      
Total current liabilities 111,993       129,676      
Deferred reimbursements 7,406       7,406      
Long-term debt 390,434       389,254      
Contingent consideration payable 7,517       16,925      
Deferred income taxes 4,896       4,896      
Operating lease liabilities 44,201       45,604      
Other non-current liabilities 6,535       6,379      
Total liabilities 572,982       600,140      
Commitments and contingencies          
Stockholders’ equity:          
Common stock, $0.01 par value, 500,000,000 shares authorized, 266,532,536 and 262,063,461 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 2,685       2,650      
Additional paid-in capital 2,364,494       2,308,578      
Accumulated other comprehensive income (loss):          
Foreign currency translation adjustment 9,255       8,412      
Unrealized loss on available-for-sale securities (173 )     (185 )    
Warrants       12,387      
Accumulated deficit (2,162,351 )     (2,045,462 )    
Total stockholders’ equity 213,910       286,380      
Total Liabilities and Stockholders’ Equity $ 786,892       $ 886,520    



TABLE 3

Amicus Therapeutics, Inc.

Reconciliation of Non-GAAP Financial Measures

(in thousands)

    Three Months Ended June 30,     Six Months Ended June 30,
      2021     2020       2021     2020  
Total operating expenses – as reported GAAP   $ 107,867   $ 107,022     $ 220,785   $ 239,052  
Research and development:                    
Share-based compensation     3,152     3,362       9,457     8,615  
Selling, general and administrative:                    
Share-based compensation     8,584     5,046       22,633     12,389  
Changes in fair value of contingent consideration payable     1,021     715       1,492     1,646  
Depreciation and amortization     1,567     2,039       3,171     3,803  
Total operating expense adjustments to reported GAAP     14,324     11,162       36,753     26,453  
Total operating expenses – as adjusted   $ 93,543   $ 95,860     $ 184,032   $ 212,599  

 



Papa John’s Expands Partnership With Drake Food Service International to Open Over 220 New Restaurants Across Latin America, Spain, Portugal and The UK by 2025

Papa John’s Expands Partnership With Drake Food Service International to Open Over 220 New Restaurants Across Latin America, Spain, Portugal and The UK by 2025

LOUISVILLE, Ky .–(BUSINESS WIRE)–
Papa John’s International, Inc. (NASDAQ: PZZA), in partnership with its largest franchisee Drake Food Service International (DFSI), today announced an expanded partnership with DFSI to open over 220 Papa John’s restaurants by 2025. This includes more than 170 across Latin America, Spain and Portugal, where DFSI currently operates in excess of 280 locations.

As part of the agreement, DFSI plans to open 50 new restaurants in the UK over the next four years, where it recently purchased over 60 Papa John’s restaurants in London, making it the brand’s largest franchisee in the country. Under the terms of this expanded partnership, DFSI will operate more than 560 Papa John’s restaurants in total by 2025.

“This growth of our partnership with Papa John’s will accelerate our efforts to deliver on our ambitious business goals, through opening new restaurants and inviting new subfranchisees to join us and grow our base of passionate Papa John’s customers around the world,” said Ignacio Astete, CEO of DFSI, which holds master franchise rights for Papa John’s in Chile, Costa Rica, Panama, Spain, Portugal and Guatemala. “Our leadership in operational excellence and technology, coupled with our commitment to the creation of shared value, combined with the love that Papa John’s has built for its brand among people across the world, has created a foundation for continuing our joint success into the future.”

“As a master franchisee of Papa John’s, DFSI has proven to be a valued and strategic partner in accelerating our development in international markets,” said Jack Swaysland, Chief Operating Officer, International at Papa John’s. “Together with DFSI – now our largest franchisee in the UK – we look forward to introducing new customers to the BETTER INGREDIENTS. BETTER PIZZA.® promise of Papa John’s.”

DFSI began operating Papa John’s restaurants in 2015 and has managed the growth of the Papa John’s brand in several of Papa John’s highest-performing international markets, including Chile. Through this expanded partnership, DFSI has now also become the country’s largest Papa John’s franchisee in the UK, one of Papa John’s best performing markets in 2020, and which continues to perform well in 2021.

In September of 2020, Papa John’s announced a new international headquarters in the UK to accelerate its strategy for international development, streamline operations and facilitate greater collaboration among teams to better support franchises around the globe – both existing and new – to successfully grow. Papa John’s is currently in 49 international countries and territories around the globe. In recent years, it has entered 11 new countries, including Spain, Portugal, Germany, Cambodia, the Netherlands, Pakistan, France, Tunisia, Iraq, Morocco, Kazakhstan, Kyrgyzstan and Poland.

About Papa John’s

Papa John’s International, Inc. (NASDAQ: PZZA) opened its doors in 1984 with one goal in mind: BETTER INGREDIENTS. BETTER PIZZA.® Papa John’s believes that using high quality ingredients leads to superior quality pizzas. Its original dough is made of only six ingredients and is fresh, never frozen. Papa John’s tops its pizzas with real cheese made from mozzarella, pizza sauce made with vine-ripened tomatoes that go from vine to can in the same day and meat free of fillers. It was the first national pizza delivery chain to announce the removal of artificial flavors and synthetic colors from its entire food menu. Papa John’s is headquartered in Louisville, Ky. and is the world’s third-largest pizza delivery company with more than 5,500 restaurants in 49 countries and territories as of June 28, 2021. For more information about the Company or to order pizza online, visit www.PapaJohns.com or download the Papa John’s mobile app for iOS or Android.

About Drake Food Service International

DFSI started operations in Chile in 2015 by acquiring 32 Papa John’s restaurants and by the close of 2021 is expected to manage 381 restaurants in seven countries. DFSI delivers growth and shared value by building a disruptive entrepreneurial environment driven by technology, a highly engaged talented team and conviction to make a positive impact in the. Our company guiding principles are Service, Excellence and Respect. For more information about the Company www.drakefsi.com.

Harrison Sheffield

Sr. Communications Manager

Papa John’s International

[email protected]

205-657-3613

Maria Menendez

Marketing Director PJ Iberia

[email protected]

+34 682 58 65 81

KEYWORDS: North America United States Europe South America Central America Kentucky

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA:

Logo
Logo